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a b s t r a c t
Crimean–Congo hemorrhagic fever (CCHF) is the most important tick-borne viral disease of humans,
causing sporadic cases or outbreaks of severe illness across a huge geographic area, from western China
to the Middle East and southeastern Europe and throughout most of Africa. CCHFV is maintained in ver-
tical and horizontal transmission cycles involving ixodid ticks and a variety of wild and domestic verte-
brates, which do not show signs of illness. The virus circulates in a number of tick genera, but Hyalomma
ticks are the principal source of human infection, probably because both immature and adult forms
actively seek hosts for the blood meals required at each stage of maturation. CCHF occurs most frequently
among agricultural workers following the bite of an infected tick, and to a lesser extent among slaugh-
terhouse workers exposed to the blood and tissues of infected livestock and medical personnel through
contact with the body fluids of infected patients. CCHFV is the most genetically diverse of the arboviruses,
with nucleotide sequence differences among isolates ranging from 20% for the viral S segment to 31% for
the M segment. Viruses with diverse sequences can be found within the same geographic area, while clo-
sely related viruses have been isolated in far distant regions, suggesting that widespread dispersion of
CCHFV has occurred at times in the past, possibly by ticks carried on migratory birds or through the inter-
national livestock trade. Reassortment among genome segments during co-infection of ticks or verte-
brates appears to have played an important role in generating diversity, and represents a potential
future source of novel viruses. In this article, we first review current knowledge of CCHFV, summarizing
its molecular biology, maintenance and transmission, epidemiology and geographic range. We also
include an extensive discussion of CCHFV genetic diversity, including maps of the range of the virus with
superimposed phylogenetic trees. We then review the features of CCHF, including the clinical syndrome,
diagnosis, treatment, pathogenesis, vaccine development and laboratory animal models of CCHF. The
paper ends with a discussion of the possible future geographic range of the virus. For the benefit of
researchers, we include a Supplementary Table listing all published reports of CCHF cases and outbreaks
in the English-language literature, plus some principal articles in other languages, with total case num-
bers, case fatality rates and all CCHFV strains on GenBank.
 2013 Elsevier B.V. All rights reserved.
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1. Introduction
Crimean–Congo hemorrhagic fever (CCHF) is the most wide-
spread tick-borne viral infection of humans, occurring across a vast
area from western China through southern Asia and the Middle
East to southeastern Europe and throughout most of Africa. The
causative agent, CCHF virus, is maintained through vertical and
horizontal transmission in several genera of ixodid (hard) ticks,
which spread the virus to a variety of wild and domestic mammals,
which develop a transient viremia without signs of illness. Human
infections occur through tick bite or exposure to the blood or other
body fluids of an infected animal or of a CCHF patient. Ticks of the
genus Hyalomma are the principal source of human infection, prob-
ably because both the immature and the adult forms actively seek
hosts for their obligate blood meals. As Hoogstraal noted in his
definitive review (1979): ‘‘[CCHFV] is remarkable among arbovi-
ruses infecting humans for the number and variety of reservoir-
vector species linked with it and the numerous ecological environ-
ments in which it circulates.’’
CCHF was first recognized as a discrete human illness in the
Crimean region of the former Soviet Union in 1944, and over
subsequent decades was reported principally in a number of
southern Soviet republics, Bulgaria and South Africa (Figs. 1
and 2).
Since 2000, however, the incidence and geographic range of
confirmed CCHF cases have markedly increased, with the disease
being reported for the first time in Turkey, Iran, India, Greece,
the Republic of Georgia, and some Balkan countries, and the detec-
tion of viral RNA in Hyalomma ticks recovered from deer in Spain
(see below). Remarkably, even though the first cases of CCHF in
Turkey were identified in 2002, more than 6300 cases have been
diagnosed in the ensuing 10 years. A large increase has also oc-
curred in Iran since the first human infection was recognized in
1999 (Chinikar et al., 2010).
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CCHF shows a spectrum of severity, from a mild, nonspecific
febrile syndrome through vascular leak, multi-organ failure, shock
and hemorrhage (Fig. 3). Probably because clinicians are most
likely to publish descriptions of patients with severe or fatal illness,
the fatality rate in case reports has ranged from 20% to 30% or high-
er (Tables 1–4 and Supplementary Table 1). In contrast, for large
case series the case fatality rate is generally lower, probably be-
cause they also include patients with milder disease; for the more
than 6000 cases reported from Turkey, it has been 5% (Table 3, Sup-
plementary Table 1).
Increasing scientific and clinical interest in CCHF has led to the
recovery and sequencing of numerous virus isolates across its geo-
graphic range, which have revealed a degree of sequence diversity
greater than that of any other arthropod-borne virus. As discussed
below, this marked genetic diversity suggests a lengthy history of
geographic dispersion of the virus in its tick vector, while the iden-
tification of CCHF viruses with diverse sequences within the same
geographic area, and of similar viruses at widely distant locations,
are consistent with the transport of virus by infected ticks on
migratory birds or through the international livestock trade (Mild
et al., 2010). Phylogenetic analysis has also revealed evidence of
genome reassortment and recombination during co-infection of a
single host, indicating the potential for the future emergence of no-
vel variants (Chamberlain et al., 2005; Hewson et al., 2004b).
2. Discovery and naming of CCHF
Although some accounts of CCHF describe it as a disease that
has only recently ‘‘emerged,’’ the wide distribution of the virus in
ticks and vertebrates across southern Asia, southeastern Europe
and Africa suggests that human infections have occurred for mil-
lennia. A severe hemorrhagic illness attributed to the bite of a tick
or louse was described in Tadjikistan in the 12th century, and
Fig. 1. Geographic distribution of CCHF. Countries in red report more than 50 human cases annually to the WHO, and those in orange report fewer than 50 cases. Countries in
yellow have not reported human cases, but CCHFV has been isolated, or its presence has been inferred from serologic studies, and a transmission-competent tick vector is also
present. The northernmost limit of Hyalomma marginatum and Hyalomma asiaticum is demonstrated by a grey, dashed line. The figure is based upon that created by the WHO
(http://www.who.int/csr/disease/crimean_congoHF/en/) and on tick distribution maps at www.kolonin.org and http://www.efsa.europa.eu/en/efsajournal/pub/1723.htm.
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similar diseases were known in other parts of Central Asia (Hoo-
gstraal, 1979). Recognition of CCHF as a discrete human illness
by modern clinicians may have been delayed because cases tend
to occur singly and sporadically in rural areas, and many patients
develop a mild, nonspecific illness, without a recognizable hemor-
rhagic fever syndrome.
The first recognized outbreak of CCHF took place in the summer
of 1944, when Soviet troops re-occupying areas of the Crimean
peninsula that had been under German occupation developed an
acute febrile illness with a high incidence of bleeding and shock
(Grashchenkov, 1945; Chumakov 1965, 1974; Hoogstraal, 1979).
Some 200 military personnel were hospitalized, and about 10%
died. An investigative team was dispatched from Moscow, led by
Mikhail Chumakov, who in collaboration with Lev Zilber had iso-
lated the causative agent of tick-borne encephalitis in the far east-
ern Soviet Union in the late 1930s. The researchers were quickly
able to link cases of the new disease to tick exposure. They noted
that, because large areas of cultivated land had been abandoned
during the German occupation, the population of hares and other
wild hosts of Hyalomma ticks had increased, and soldiers and farm
workers engaged in restoring agricultural production were suffer-
ing large numbers of tick bites. Chumakov and his colleagues soon
succeeded in proving that ‘‘Crimean hemorrhagic fever’’ (CHF) was
a tick-borne viral infection by inoculating psychiatric patients and
military volunteers with ultrafiltrates of patient serum or extracts
of pooled ticks (Chumakov, 1965, 1974). Although they initially
claimed to have reproduced the disease in a variety of experimen-
tal animals, their subsequent reports attributed those results to
microbial contamination.
For more than two decades after the identification of CHF, lab-
oratory research was limited by the inability to culture its causa-
tive agent. However, studies by Work, Casals and others during
the early 1960s had shown that a number of arboviruses could
be propagated by intracerebral inoculation in newborn mice, and
a critical breakthrough in CHF research came in 1967, when
Chumakov’s group discovered that newborn mice developed a
Fig. 2. Total number of reported cases of CCHF by country, based on published articles (see Tables 1–4 and Supplementary Table 1). The total number of cases increases with
the darkness of the coloration, as defined by the key. Certain countries, such as Uzbekistan and Kyrgyzstan, have reported cases to the WHO, as indicated in Fig. 1, but there
are no epidemiological data in the published literature.
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lethal illness when injected with samples from CCHF patients or in-
fected ticks (Chumakov et al., 1968). The use of suckling mice to
cultivate virus, titrate samples and produce antigens for immuno-
logic assays led to a rapid increase in research on the circulation of
CHFV in nature and to test human and animal sera for the presence
of virus-specific antibodies. Inoculation of newborn mice continues
to play an important role as a sensitive detection method for
arboviruses.
By the late 1960s, Soviet researchers had selected the Drozdov
isolate of CHFV, recovered from a patient in Astrakhan, as a stan-
dard reference strain (Butenko et al., 1968; Chumakov, 1974).
Using the suckling mouse method and immunologic assays, they
were able to show that a variety of febrile diseases found in widely
separate foci in the Soviet Union and in Bulgaria were caused by
strains of CHFV (Chumakov et al., 1970). The known geographic
range of the disease was further widened in 1969, when Casals dis-
covered that the Drozdov virus, provided to him by Chumakov, was
identical to an agent that had been isolated in the Belgian Congo
(present Democratic Republic of the Congo, DRC) in 1956 and des-
ignated ‘‘Congo virus’’ (Casals, 1969). Since its identification in the
DRC, Congo virus had been recovered from animals and ticks in
Nigeria and Uganda, and it appeared to be widespread in Africa
(see below). Casals et al. (1970) proposed that all of these agents
be given the single name ‘‘CHF-Congo virus’’, which was eventually
simplified to CCHFV.
In contrast to the Drozdov strain, which was recovered from a
patient, the virus used as a reference strain by western scientists,
IbAr 10200, was isolated from a tick collected from an apparently
healthy camel in Nigeria in 1966 (Causey et al., 1970). At that time,
human infections had not been reported in the region, but this may
simply have reflected a limited surveillance capacity and the spo-
radic nature of tick-borne diseases, as there is no evidence that
African strains of CCHFV are less virulent than those in other re-
gions. Amplified through sequential passage in suckling mice, the
IbAr 10200 virus was transferred to the Yale arbovirus collection
and other laboratories, and has been the only strain of CCHFV
available to most investigators for the past few decades.
The introduction of the technique of virus culture in newborn
mice in the late 1960s led to an explosion of research on CCHF,
so that by the end of the following decade Hoogstrall was able to
cite more than 500 articles in his definitive review (Hoogstraal,
1979). Many of these publications, including a large number of
translations from the Russian and Bulgarian literature, are avail-
able from the web site of the US Armed Forces Pest Management
Board at http://www.afpmb.org/content/literature-retrieval-
system.
3. The causative agent
3.1. Classification
CCHFV is a member of the genus Nairovirus in the family Bunya-
viridae, which also includes the genera Orthobunyavirus, Hantavi-
rus, Phlebovirus and Tospovirus. The nairoviruses are tick-borne
viruses, which are distinguished from other bunyaviruses by their
large L segments (see below). They are divided into seven sero-
groups; CCHFV and Hazara virus (HAZV) make up the CCHF sero-
group. HAZV was isolated from ticks recovered from wild rodents
in Pakistan (Begum et al., 1970; Dowall et al., 2012a). It has not
been known to cause disease in humans.
3.2. Virion structure, genome organization and encoded proteins
The CCHF virion is spherical and approximately 80–100 nm in
diameter (Fig. 4). Its lipid envelope is studded with spikes consist-
ing of the glycoproteins GN and GC, which are responsible for virion
Fig. 3. Clinical presentation of Crimean–Congo hemorrhagic fever. Severely ill
patients often develop a striking pattern of large ecchymoses, not seen in other
types of viral hemorrhagic fever. (Courtesy of Dr. Hürrem Bodur, Ankara, Turkey.)
Table 1
Summary of published reports of CCHF in regions of the former Soviet Union and southeastern Europe, with total cases per country, case fatality rate and identification of virus
clade (when available). Data on total cases and case fatality rates were obtained from the articles cited. See Supplementary Table 1 for more detailed information.
Years Country/region Total cases Case fatality rate Clade Reference
1944 Crimea 161 11 Hoogstraal (1979)
1953–1963 Astrakhan 104 17 Europe-V Hoogstraal (1979)
1953–1968 Stavropol 25 44 Europe-V Hoogstraal (1979)
1963–1969 Rostov 323 15 Hoogstraal (1979)
1953–2009 Bulgaria 2431 17 Europe-V Hoogstraal (1979), Papa et al. (2004), ECDC (2008), Christova et al. (2009) and Ergonul (2010)
1995–2010 Kosovo 216 19 Europe-V EpiSouth and WHO (2008), EpiSouth (2012) and WHO SEARO (2011)
1999–2008 Russia >1150 3.2 Europe-V Yashina et al. (2003a, 2003b), EpiSouth and WHO (2008), and Leblebicioglu, 2010
2001–2006 Albania 32 3 Europe-V Papa et al. (2002a), EpiSouth and WHO (2008)
2008 Greece 1 100 Europe-V Papa et al. (2008)
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binding to cellular receptors (Fig. 5). Neutralizing antibodies to GN
and GC are produced during the course of infection. Virions contain
the negative-sense small (S), medium (M) and large (L) genome
segments, encapsidated by the nucleoprotein (NP), plus the RNA-
dependent RNA polymerase (RdRp), to initiate transcription and
genome replication in the host cell. The terminal complementary
sequences 50-UCUCAAAGA and 30-AGAGUUUCU are conserved in
all nairoviruses (Clerex-Van Haaster et al., 1982) (Morikawa
et al., 2007). Intra-strand base-pairing between the terminal nucle-
otides leads to the formation of stable panhandle structures and
non-covalently closed circular RNA molecules. By inference from
other bunyaviruses, terminal base-pairing provides the functional
promoter regions for interaction with the viral RdRp (Marriott
and Nuttall, 1996).
3.2.1. The S segment
The S segment encodes the NP, which is made up of a large
globular domain, to which N- and C-terminal portions of the poly-
peptide contribute, plus a protruding ‘‘arm’’ containing a conserved
caspase-3 cleavage site (Karlberg et al., 2011; Carter et al., 2012).
The globular region is responsible for RNA binding. Encapsidation
of virion RNA involves the oligomerization of NP, brought about
by head-to-tail interactions of the protein to form a helical struc-
ture (Wang et al., 2012).
The role of the caspase-3 cleavage site in virus replication is not
known. NP is cleaved in apoptotic cells late in infection (Karlberg
et al., 2011); cleavage may play a regulatory role, as its inhibition
enhanced RNA polymerase activity (Wang et al., 2012). Unexpect-
edly, structural alignment of the CCHFV NP with the NPs of other
RNA viruses showed that it is most closely related to the arenavi-
rus, Lassa virus. Bacterially-expressed NP can be used in an ELISA
to detect virus-specific IgG (Samudzi et al., 2012).
3.2.2. The M segment
The M segment encodes a single polyprotein, from which two
type I transmembrane glycoproteins, GN and GC, are produced
through cotranslational cleavage and extensive post-translational
processing, beginning in the endoplasmic reticulum (ER) and con-
cluding in the Golgi body (Figs. 5 and 6) (Altamura et al., 2007; Ber-
tolotti-Ciarlet et al., 2005). The polyprotein is first cleaved by a host
signal peptidase into 140 kDa PreGN and 85 kDa PreGC segments.
PreGN is then further cleaved at a number of conserved recognition
sites by the host proteases SKI-1 and furin, generating the 58 kDa
GN and liberating several small protein fragments, including a non-
structural NSm protein, similar to that which has been identified in
other bunyaviruses (Sanchez et al., 2006; Altamura et al., 2007). In
cells that lack SKI-1, PreGN and PreGC accumulate in the Golgi
apparatus, and infected cells secrete virus particles lacking surface
glycoproteins (Bergeron et al., 2007).
Table 2
Summary of published reports of CCHF in eastern and central Asia, with total cases by country, case fatality rate and identification of virus clade (when available). Data on total
cases and case fatality rates were obtained from the articles cited. See Supplementary Table 1 for more detailed information.
Years Country/region Cases Case fatality rate Clade References
1965–1997 China 286 21 Asia-2 IV; M1; M2; M3 (Papa et al. (2002c)
1948–2000 Khazakhstan 108 35 Hoogstraal (1979) and Yashina et al. (2003)
1943–2010 Tajikistan 237 16 Asia-2 IV; M2 Hoogstraal (1979), Seregin et al. (2004) and Ergonul (2010)
1976–2000 Pakistan 23 39 Asia-1 IV; M1; M2; Asia-IV Burney et al. (1980) and Smego et al. (2004)
2011 India 6 83 Asia-2 IV; M2; Asia-IV Yadav et al. (2013)
Table 3
Published reports of CCHF in the Middle East and Turkey with total cases, case fatality rate and identification of virus clade (when available). Data on total cases and case fatality
rates were obtained from the articles cited. See Supplementary Table 1 for more detailed information.
Years Country/region Cases Case fatality
rate
Clade References
1979–1995 United Arab Emirates 18 61 Asia-2 IV Suleiman et al. (1980), Schwarz et al. (1997)
and Watts et al. (1989)
1990 Saudi Arabia 7 0 El-Azazy and Scrimgeour (1997)
1995–1997 Oman 4 Asia-1 IV; M1; Asia-IV Saluzzo et al. (1985)
1979–1980 Iraq 55 64 Asia-1 IV; M2; Asia-IV Al-Tikriti et al. (1981), Tantawi et al. (1980)
2000–2008 Iran 534 15 Asia-1 IV; Africa-3; Europe-1 V. Chinikar et al. (2010)
2008–2012 Afghanistan 51 47 Asia-1 IV; M2; Asia-IV Mustafa et al. (2009), Mofleh and Ahmad (2012),
Olschlager et al. (2011) and Atkinson et al. (2012a, 2012b)
2002–2009 Turkey 4431 5 Europe-V Maltezou et al. (2009)
Table 4
Summary of reports of CCHF in Africa, with total cases by country, case fatality rate and identification of virus clade (when available). Data on total cases and case fatality rates
were obtained from the articles cited. See Supplementary Table 1 for more detailed information.
Years Country/region Cases Case fatality rate Clade References
1956 Zaire (DRC) 2 0 Central Africa-II Hoogstraal (1979)
1958–1977 Uganda 12 8 Central Africa-II Hoogstraal (1979)
1983–2004 Mauritania 39 28 Watts et al. (1989), Saluzzo et al. (1985)
and Nabeth et al. (2004a, 2004b)
1983 Burkina Faso 1 0 Watts et al. (1989)
1981–1986 South Africa 32 31 S Africa/W Africa-III; M1; M2 Watts et al. (1989)
1986 Tanzania 1 0 Watts et al. (1989)
2000 Kenya 1 100 Dunster et al. (2002)
2008–2010 Sudan 12 75 S Africa/W Africa-III; M2 Aradaib et al. (2011) and Elata et al. (2011)
164 D.A. Bente et al. / Antiviral Research 100 (2013) 159–189
N-linked glycosylation of GN is also essential for the final pro-
cessing of both glycoproteins (Erickson et al., 2007). GN performs
a chaperone-like function for GC, and must be present for correct
folding to occur (Shi et al., 2012). CCHFV glycoproteins contain
an exceptionally large number of cysteine residues, suggesting
the presence of many disulfide bonds and a complex secondary
structure. The N-terminus of GN has mucin-like features, with
the potential for extensive O-glycosylation (Sanchez et al.,
2002; Papa et al., 2002c; Bertolotti-Ciarlet et al., 2005). Interest-
ingly, the C-terminal cytoplasmic tail of GN contains two zinc
fingers, which can bind viral RNA (Estrada and De Guzman,
2011).
3.2.3. The L segment
The L segment of CCHFV and other nairoviruses is nearly twice
the size of those of other bunyaviruses. Its single open reading
frame, more than 12,000 nucleotides in length, encodes a nearly
4000-amino acid polyprotein, which contains an ovarian tumor
protease (OTU) domain near its N-terminus, followed by segments
homologous to viral topoisomerase, zinc finger and leucine zipper
motifs, and a RdRp catalytic domain near the C-terminus (Honig
et al., 2004a). The latter show extensive sequence identity with
Dugbe virus, another member of the Nairovirus genus. The pres-
ence of the OTU cysteine protease near the N terminus suggests
that the L polyprotein is autocatalytically cleaved during transla-
tion; however, deletion of the OTU had no apparent effect on viral
replication in a minigenome system (Bergeron et al., 2010). To
date, the only demonstrated role of the OTU is the removal of
ubiquitin from cellular proteins, which may serve to counter
host-cell antiviral mechanisms (Frias-Staheli et al., 2007).
3.3. Replication cycle
The cellular receptor for CCHFV has not been identified, but a
recent study employing the soluble ectodomains of GN and GC
suggested that GC plays the major role in binding to target cells,
and identified the host molecule nucleolin as essential for cell en-
try (Xiao et al., 2011). The virus appears to enter host cells by
clathrin-dependent endocytosis (Fig. 5) (Simon et al., 2009b).
Once within the cytoplasm, the viral RdRp interacts with the
encapsidated genome segments to synthesize complementary po-
sitive-strand intermediates, which are used as templates for neg-
ative-strand synthesis. A model has been proposed involving
primer-independent synthesis of both positive-sense antigenomes
and negative-sense progeny genomes. (Schmaljohn and Nichol,
2007).
The processes of internalization, virion assembly and egress are
dependent on host-cell microtubules (Simon et al., 2009a). As
noted above, synthesis of the virion surface glycoproteins is a com-
plex process, which begins with synthesis of PreGN and PreGC in
the ER, their transit as a heterodimer to the Golgi body, and their
further cleavage, glycosylation, folding and integration into virion
membranes (Shi et al., 2012), Budding of mature virus particles oc-
curs within the Golgi body.
Fig. 4. Schematic depiction of the CCHF virion. The virion is spherical and approximately 80–100 nm in diameter. Its lipid envelope is studded with spikes consisting of the
glycoproteins GN and GC. The virion contains three single-stranded RNA genome segments (small, medium, and large), encapsidated by the nucleoprotein (NP), plus the RNA-
dependent RNA polymerase (RdRp).
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Fig. 5. Intracellular replication cycle of CCHFV. Virions bind to cell surface receptors (A), and are internalised through clathrin-dependent, receptor-mediated endocytosis (B).
Reduced pH in the endosome leads to a conformational change in the viral glycoproteins resulting in fusion between the envelope and endosomal membranes, allowing the
nucleocapsids to be released into the cytosol (C). After dissociation of the nucleocapsids (D), messenger RNA (mRNA) and complementary RNA (cRNA) are generated by the
RNA-dependent RNA-polymerase (RdRp). The mRNA is translated into viral proteins, while the cRNA is used as a template for genomic vRNA production (E). The vRNA, RdRp
and capsid proteins associate to form new nucleocapsids. Glycoprotein translation occurs in the endoplasmic reticulum (F), where the precursor protein is cleaved into GN and
GC precursor forms. The glycoproteins are transported to the Golgi complex (G), where further processing takes places (H). New virions are formed (I) once final glycoprotein
maturation has taken place, and are transported to the plasma membrane and released (J).
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4. Maintenance and transmission of CCHFV
In the nearly 70 years since CCHF was recognized as a human
disease, researchers have characterized the general features of
the circulation of its causative agent among ticks and various spe-
cies of small and large mammals. The role of ticks in the mainte-
nance of the virus has been established both through studies of
field-collected ticks and in experimental assessments of vector
competence in the laboratory. In contrast, because most verte-
brates infected with CCHFV apparently develop only a transient
viremia without apparent illness, the identification of mammalian
hosts of CCHFV has been based largely on the detection of virus-
specific antibodies in serum collected from livestock or occasion-
ally from wild animals. Routes of transmission to humans have
been identified based on the exposure histories of patients and
on the detection of antibodies to CCHFV in serum samples from
populations in endemic areas.
4.1. Tick vectors of CCHFV
Ticks are arachnids in the class Ixodida; those in the family
Argasidae have a soft body, while members of the family Ixodidae
possess a rigid shield or scutum. Ticks acquire the nutrients they
need for their metamorphosis from larva to nymph to adult by tak-
ing blood from a vertebrate (hematophagy) once during each
developmental stage (instar). Adult females must also take a blood
meal to obtain the nutrients needed to produce eggs. Feeding takes
place through a specialized organ, the hypostome. It is facilitated
by the presence in tick saliva of anticoagulants and immunomod-
ulatory proteins, which may facilitate virus infection and elicit a
specific immune response in the host, making it partially resistant
to further infestation (Francischetti et al., 2009; Willadsen, 2004).
CCHFV is maintained through trans-stadial, transovarial and
venereal transmission in several species of ixodid (hard) ticks,
accompanied by bursts of amplification each spring and summer,
when the ticks transmit the virus to mammals while taking the
blood meals required for their maturation and for egg production
(Fig. 6). The resulting viremia in mammals is transient, but ticks re-
main infected throughout their several-year lifetimes; they are
therefore the true natural reservoirs. Because humans are not a
source of infection for ticks, they are only accidental, ‘‘dead-end’’
hosts for the virus.
A critical area of research on the maintenance of CCHFV in nat-
ure has been the identification of its competent tick vectors, i.e.
those species that undergo life-long viral infection, and in which
the agent is efficiently transmitted from adult females to their eggs
and from adult males to females through copulation. Unfortu-
nately, some researchers attempting to identify tick species
responsible for human disease have focused only on detecting viral
antigen, genomic sequences or infectious virus in wild-caught
ticks, ignoring the fact that any arthropod that has taken a blood
meal from a CCHFV-infected vertebrate will be positive in such
tests, whether or not it is capable of maintaining the virus through
vertical and venereal transmission. As discussed below, competent
vectors of CCHFV can only be identified through careful laboratory
Fig. 6. Processing of the protein products of the three CCHFV genome segments. Transcription and translation of the S segment results in production of the nucleoprotein
(NP). In contrast to some other bunyaviruses, CCHFV does not produce a small nonstructure (NSs) protein. Similarly, transcription and translation of the L segment gives rise
to a single protein, the RNA-dependent RNA polymerase, or L protein. In contrast, the M genomic segment encodes a polyprotein, which undergoes a series of cleavages by
host-cell enzymes and further modifications in the Golgi apparatus to produce the glycosylated GN and GC proteins (see text for additional details).
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studies to confirm the occurrence of transovarial and venereal
transmission of virus.
In considering the maintenance of CCHFV in nature, it is essen-
tial to realize that some species of ticks may harbor the virus and
transmit it among small and large animal mammals, without ever
serving as a source of human infection. Because humans who enter
an enzootic focus are most likely to be bitten by questing Hya-
lomma ticks, the role of other species in maintaining the virus
may not be evident. Surveys of ticks recovered from wild and
domestic animals are a first step in identifying potential reservoir
species, but studies of vector competence are required to confirm
their role in virus maintenance.
4.1.1. Ticks, nairoviruses and CCHFV
Most members of the genus Nairovirus are transmitted by ticks.
While most of these viruses are associated with only a single tick
genus, viruses in the CCHF serogroup may be transmitted by sev-
eral different genera of ticks. However, while some nairoviruses in-
fect argasid (soft) ticks, CCHFV are maintained exclusively in ixodid
ticks. Experimental studies have shown that when soft ticks are
experimentally infected with CCHFV, the virus fails to spread to
its tissues or persist through its trans-stadial development (Durden
et al., 1993; Shepherd et al., 1989b). Although the virus has been
isolated from other arthropods, such as biting midges (Causey
et al., 1970), this is believed to simply reflect recent feeding on a
viremic mammal; there is no evidence that mosquitoes or any
arthropod species other than ixodid ticks is a competent vector
for CCHFV.
The marked genetic diversity of the nairoviruses appears to re-
flect their long history of co-evolution with their tick reservoirs,
which have themselves evolved along with the vertebrates on
which they depend for sustenance (Honig et al., 2004b). Similarly,
the association of CCHFV with several tick species and the exploi-
tation by ticks of a variety of vertebrate hosts as sources of blood
meals may contribute to the wide sequence diversity of the virus.
Although recombination and reassortment might potentially take
place in a mammal simultaneously infected with two strains of
virus, the transient nature of such infections suggests that genetic
exchange is much more likely to occur in persistently infected
ticks, as they continue to acquire new virus variants over their
life-times. The nature and extent of CCHFV evolution in ticks will
be an important topic for future laboratory research.
4.1.2. Vertical transmission
Competent tick vectors of CCHFV are defined by their ability to
support viral replication in their tissues during metamorphosis
from larva to nymph to adult, to transmit the virus from adult fe-
males to their eggs and from adult males to females during copu-
lation (Dohm et al., 1996; Gordon et al., 1993; Logan et al., 1990;
Shepherd et al., 1991; Gonzalez et al., 1992). Following its inges-
tion by a competent vector in a blood meal, CCHFV replicates in
the lining of the tick’s midgut, then spreads to many different tis-
sues, reaching the highest titers in the salivary glands and repro-
ductive organs (Dickson and Turell, 1992). Because a female may
produce thousands of eggs, even a low rate of transovarial trans-
mission is sufficient to maintain a large population of infected ticks
(Nuttall et al., 1994). However, little is known about factors that
influence the percentage of eggs that become infected.
4.1.3. Horizontal transmission
The spread of CCHFV between ticks and mammals takes place
principally during the spring and summer months, when larvae
and nymphs take the blood meals required for their growth and
metamorphosis, and adult females are preparing to produce eggs
(Fig. 6). In some vertebrate species, the bite of an infected tick is
followed by the replication of virus in tissues and its spread in
the bloodstream, providing a source of infection for additional
ticks. A feeding tick may remain attached for several weeks,
enhancing the likelihood of virus transmission from an infected
tick to its host, or from a viremic host to its feeding, virus-naïve
ticks. However, experimental studies indicate that not all mam-
mals are susceptible to infection with CCHFV, or develop a
Fig. 7. Life cycle of Hyalomma spp. ticks and vertical and horizontal transmission of CCHFV. The course of the tick life cycle is indicated with blue arrows. Upon hatching,
larvae find a small animal host for their first blood meal (hematophagy). Depending on the tick species, the larvae either remain attached to their host following engorgement
and molt in place (two-host ticks) or fall off and molt (three-host ticks); this transition is marked by an asterisk. The nymphs then either continue to feed on the animal on
which they molted (two-host ticks) or attach to a new small animal (three-host ticks). Upon engorgement, nymphs of all species drop off their host and molt into adults. Adult
ticks then find a large animal for hematophagy, and mate while attached to the host. After taking a blood meal, the engorged females drop off and find a suitable location for
ovipositing. During the tick life cycle, there are a number of opportunities for virus transmission between ticks and mammals (solid red arrows) and directly between ticks,
through co-feeding (dashed arrows). For each form of virus transfer, the thickness of the red arrow indicates the efficiency of transmission. Infection of humans can occur
through the bite of an infected tick or through exposure to the body fluids of a viremic animal or CCHF patient.
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sufficiently high blood viral titer to efficiently infect ticks (Shep-
herd et al., 1989a; Shepherd et al., 1991). Tick species also differ
in the quantity of ingested virus that is required to initiate infec-
tion of the lining of the midgut (Shepherd et al., 1991).
Evolution has dealt with these uncertainties by providing a sec-
ond transmission mechanism, in which virus present in tick saliva
can spread directly to other ticks feeding nearby (‘‘co-feeding’’)
(Jones et al., 1987b; Nuttall and Labuda, 2003; Nuttall and Labuda,
2004). Since it does not require the host animal to be viremic, this
mechanism of virus transfer between ticks is also known as ‘‘non-
viremic’’ transmission. Substances present in tick saliva appear to
enhance the transmission of virus by co-feeding (Shepherd et al.,
1989b). In adult females, such direct exposures may enhance the
rate of transovarial transmission (Gonzalez et al., 1992; Nuttall
et al., 1994; Randolph, 2011).
Once an immature tick has completed a blood meal, it may re-
main on its host while molting to its next instar, or drop off, molt
and seek a new host. Certain members of the genus Hyalomma,
such as Hyalomma marginatum, are ‘‘two-host’’ ticks, which as lar-
vae and nymphs feed on rodents, hares, ground-feeding birds or
other small animals while feeding and molting, but feed on sheep,
cattle and other large mammals as adults (Fig. 7). Other species are
‘‘three-host’’ ticks, which drop off their host each molt. Specific
tick-host cycles therefore have a strong influence on the circulation
of CCHFV in its natural foci. Some species wait passively to encoun-
ter a vertebrate (‘‘ambush ticks’’), but Hyalomma are ‘‘hunting’’
ticks, which can quest up to 400 m to find their hosts (including
humans). The role of ground-feeding birds in the maintenance
and spread of CCHFV is discussed below.
4.1.4. Competent tick vectors and their geographic distribution
The geographic distribution of CCHF in Eurasia largely reflects
that of Hyalomma ticks. H. marginatum is the principal vector in
the region extending from Kosovo to Pakistan, and is the tick most
commonly recovered from humans and animals in endemic re-
gions of Turkey (Ozdarendeli et al. 2010). The broad dispersal of
Hyalomma ticks reflects their tolerance of diverse environments,
including savannah, steppe and lightly wooded areas, and the abil-
ity of their aggressively questing larvae and nymphs to feed on a
variety of hosts, including hedgehogs, hares and ground-feeding
birds, while the adults actively seek out sheep, cattle and other
large animals (reviewed in Hoogstraal (1979)). The northern limit
for members of the genus appears to be set by the length of the
warm season; thus, Hyalomma lusitanicum, from which CCHFV
RNA was recently recovered (Estrada-Pena et al., 2012c), is found
in southern Spain, but not in colder northern parts of the country
(Barandika et al., 2011).
Other members of the genus Hyalomma, including Hyalomma
marginatum rufipes, are the major vectors of CCHFV in Africa, where
the proximity of numerous wild vertebrates to livestock farms may
favor the existence of large tick populations and human exposures
to the virus (Rechav, 1986). The virus has also been recovered from
other thermophilic tick species, including Rhipicephalus ticks in
Turkey, Greece and Albania (Yesilbag et al., 2013) (Gargili et al.,
2011) (Papadopoulos and Koptopoulos 1978) (Papa et al., 2011;
Papa et al., 2009b) and Dermacentor marginatus in Turkey (Yesilbag
et al., 2013).
As noted above, the detection of CCHFV in a wild-caught tick
may only indicate that it has recently fed on an infected mammal,
not that it is a competent vector. To avoid reaching incorrect con-
clusions as to the role of various tick species in maintaining the
virus, some researchers have attempted to identify competent vec-
tors by confirming the persistence of virus throughout the matura-
tion process and across generations, and by testing the ability of
experimentally infected ticks to transmit infection to suckling mice
or other laboratory animals. Hoogstraal (1979) reviewed a large
number of such studies performed by Soviet and other investiga-
tors from 1945 to the late 1970s, demonstrating trans-stadial
and transovarial transmission of CCHFV in H. marginatum and
other species. Table 5 summarizes a number of experimental stud-
ies performed since that time, which have investigated CCHFV
infection of Hyalomma, Rhipicephalus and Dermacentor ticks. In
many cases, ticks were infected through intracoelomic or intra-
anal inoculation, bypassing the normal route of infection through
the ingestion of a blood meal; only those studies in which ticks
were fed on viremic suckling mice provide solid evidence of vector
competence. As shown in the table, little research in this area has
been published since 1999, possibly reflecting the introduction of
more rigorous biocontainment measures for work with CCHFV.
Table 5
Experimental studies of the replication of CCHFV in various tick species, the occurrence of trans-stadial and transovarial transmission and the ability of infected ticks to transmit
the virus to animals. The method of tick infection is noted for each study; only those studies in which ticks were exposed to CCHFV through a virus-containing blood meal provide
evidence of vector competence, by duplicating the natural infection cycle.
Year Experimental design and principal findings References
1970 Nymphal H. marginatum rufipes parenterally inoculated with Congo virus remained persistently infected and transmitted virus to a calf Lee and Kemp (1970)
1976 Demonstrated trans-stadial and transovarial virus transmission and infection of vertebrates by H. plumbeum, Rhipicephalus rossicus and
Dermacentor marginatus fed on infected susliks
Kondratenko (1976)
1989 Infected adult H. m. rufipes, H. truncatum and R .e. mimeticus ticks transmitted CCHFV to sheep; virus inoculated intracoelomically into
nymphs persisted in adults
Shepherd et al.
(1989b)
1989 Larval H. truncatum were fed on viremic newborn mice; trans-stadial and horizontal transmission were demonstrated; no transovarial
spread
Logan et al. (1989)
1990 Hyalomma and Rhipicephalus ticks were inoculated intracoelomically; virus persisted longer in ticks given a blood meal; no transovarial
transmission
Logan et al. (1990)
1991 Nymphs and adults of H. rufipes and Amblyomma variegatum were infected by intracoelomic inoculation with Congo virus Okorie (1991)
1991 Compared levels of viremia and transmission of CCHFV from infected sheep, cattle and scrub hares to immature and adult Hyalomma
and Rhipicephalus
Shepherd et al.
(1991)
1991 Adult H. truncatum inoculated intra-anally with CCHFV remained infected for several months Gonzalez et al.
(1991)
1992 Adult H. truncatum infected intra-anally with CCHFV transmitted virus by co-feeding and from male to female by the venereal route Gonzalez et al.
(1992)
1992 H. truncatum were infected intracoelomically; virus titers reached highest levels in salivary glands and reproductive tissues, were
boosted by a blood meal
Dickson and Turell
(1992)
1993 Argasid ticks (Ornithodoros sonrai) fed on viremic suckling mice did not remain persistently infected Durden et al. (1993)
1996 Larval H. impeltatum fed on infected newborn mice transmitted virus transstadially and to guinea pigs Dohm et al. (1996)
1999 Intracoelomic inoculation of larvalH. m. rufipes and H. truncatum resulted in trans-stadial and transovarial persistence, but virus lost
from subsequent generation
Faye et al. (1999)
2007 H. marginatum experimentally infected through a blood meal and held at 4 C transmitted virus after 10 months, and virus remained
detectable after two years
Turell (2007)
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4.2. Infection of wild and domestic mammals
The three decades following the identification of CHF in 1944
saw a remarkable effort, principally by Soviet and Bulgarian scien-
tists, to identify tick vectors and vertebrate hosts of the virus in the
Soviet Union and neighboring countries (Hoogstraal, 1979). Begin-
ning in the late 1960s, the use of newborn mice to isolate and prop-
agate the virus led to a further expansion of research, including
numerous studies of the circulation of ‘‘Congo virus’’ in ticks and
vertebrates in central Africa in the 1970s and of CCHFV in South
Africa in the 1980s (reviewed by Nalca and Whitehouse, 2007).
4.2.1. Identification of vertebrate hosts
Serosurveys of domestic animals have been the traditional
means of identifying regions where CCHFV is circulating. In gen-
eral, such studies have shown that antibody positivity in livestock
animals correlates with the occurrence of human cases; that the
percentage of positive animals tends to rise and fall with seasonal
levels of tick parasitism; and that seropositivity is more common in
adult than young animals. Wild and domestic animal hosts that
have been identified through serosurveys and other ecologic stud-
ies are discussed below.
The requirement of Hyalomma and other tick vectors for blood
meals from both small and large animals during the course of their
maturation helps to explain some epidemiologic features of CCHF.
In regions where small mammals such as hares and hedgehogs and
large mammals such as sheep and cattle are abundant, the virus
may circulate silently, with human cases occurring only occasion-
ally, when farmers handling livestock are bitten by infected ticks.
In contrast, when a region has many small mammals, but few large
ones, any humans who enter the area may be actively sought out
by questing adult ticks, resulting in a large number of infections.
This appears to have been the situation in 1944 in the Crimea,
where wild hares had proliferated on abandoned farms during
the German occupation, but the number of livestock was sharply
reduced. The explosion of cases among soldiers and collective farm
workers re-settling the area reflected the urgent need of questing
adult Hyalomma to find a large animal source for their next blood
meal. Similar situations may explain the presence of ‘‘hot spots’’ of
CCHFV in other regions, such as in Turkey.
4.2.2. Experimental infections of wild and domestic animals
A number of experimental studies have attempted to character-
ize CCHFV infection of wild or domestic vertebrates. This work has
provided a limited amount of data on the duration and magnitude
of viremia, in some cases quantitating virus transmission from and
to feeding ticks. Many such reports appeared in the Russian-lan-
guage literature in the period 1945–1978, and most are available
in translation from the AFPMB web site cited above; they are re-
viewed in detail by Hoogstraal (1979), and some are summarized
by Nalca and Whitehouse (2007). In general, these studies found
low-level viral replication in horses, donkeys, sheep, cattle and
other animals in CCHF-endemic areas, in the absence of any clear
signs of illness. Since they have not been repeated using modern
laboratory methods, the validity of the findings is uncertain.
Since 1970, only 7 reports of the experimental infection of wild
and domestic animals with CCHFV have been published in the Eng-
lish-language literature (Table 6). These studies found that sheep,
calves, scrub hares and ostriches became viremic, and in some
cases transmitted the virus to feeding ticks. These limited data per-
mit few conclusions as to role of various animal species in the
maintenance of CCHFV in enzootic areas. There is a great need to
perform similar studies, using modern research methods, to char-
acterize in detail the ability of domestic animals to support the cir-
culation of CCHFV and to serve as a source of human infection via
ticks or exposure to tissues and body fluids.
4.3. Features of an enzootic focus
Ticks are most abundant where sources of blood meals are
numerous and a long warm season permits their maturation from
larva to adult before the onset of cold weather. The geographic dis-
tribution of each CCHFV-competent tick vector is therefore defined
by the range of its vertebrate hosts and the environmental condi-
tions required for it to reach adulthood. At any given location,
the vector’s population density will change from year to year,
depending on the availability of vertebrate hosts, weather condi-
tions, changes in vegetation and other factors that affect the suc-
cess of molting and egg production (Estrada-Pena et al., 2012b).
Because CCHFV does not cause overt signs of illness in host ani-
mals, the only evidence that the virus is circulating in a given geo-
graphic focus is the occurrence of disease in human ‘‘sentinels.’’ In
the presence of a competent tick vector, the hazard to local resi-
dents will depend upon the population density of the tick, the
prevalence of infected ticks, and the frequency of bites. The tick–
human contact rate is increased by activities such as farming and
hunting, and may be further multiplied if a population is deprived
of shelter or otherwise forcibly exposed to their local environment,
as may occur during warfare or natural disasters.
Although cases of CCHF resulting from tick bite tend to occur
sporadically, epidemics may be seen under conditions of heavy tick
exposure. As noted above, this occurred in the Crimea in 1944,
when soldiers sent to reclaim abandoned collective farms were ex-
posed to large numbers of ticks infesting a markedly expanded
wild hare population. A similar phenomenon was apparently
responsible for the sharply increased incidence of CCHF in Bulgaria
in the 1950s, as forest, wetlands and other uncultivated areas were
converted to farming during the enforced collectivization of agri-
culture. Human exposure to an expanded number of small verte-
brate hosts of Hyalomma ticks may also have contributed to the
recent explosion of cases in Central Turkey, when residents re-
turned to farms abandoned during civil strife. Such geographic
Table 6
Experimental infections of wild and domestic animals with CCHFV.
Year Experimental design and principal findings References
1970 Two calves inoculated with Congo virus developed a mild illness; a tick fed on one of them tested positive for virus Causey et al. (1970)
1989 Infected 11 different wild animal species; viremia was detected in scrub hares and some rodents, but only in scrub hares was it high
enough to infect ticks
Shepherd et al.
(1989a)
1991 Compared levels of viremia and transmission of CCHFV from infected sheep, cattle and scrub hares to immature and adult Hyalomma and
Rhipicephalus
Shepherd et al.
(1991)
1991 Adult H. truncatum fed on experimentally infected sheep became infected and transmitted virus transovarially Wilson et al. (1991)
1994 H. m. rufipes larvae became infected when fed on hornbills and starlings inoculated with CCHFV Zeller et al. (1994)
1998 West African sheep inoculated with CCHFV developed viremia, fever and mild hepatic dysfunction Gonzalez et al.
(1998)
1998 Young ostriches inoculated with CCHFV were viremic on days 1–4 postinfection Swanepoel et al.
(1998)
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‘‘foci’’ of intense disease transmission are also seen in other tick-
borne diseases, such as Omsk hemorrhagic fever and Kyasanur for-
est disease.
4.4. Role of birds in the maintenance and spread of CCHFV
The larvae and nymphs of Hyalomma and other multiple-host
ixodid ticks frequently take their blood meals from ground-feeding
birds, and often remain attached to them while molting. However,
there is no evidence that birds fed upon by CCHFV-infected ticks
become viremic. Hoogstraal (1979) cited a number of Russian re-
ports of the recovery of infected ticks from a variety of bird species,
but noted that birds were apparently not hosts for viral replication.
This conclusion was supported by the only two subsequent
studies, as researchers were unable to detect antibodies to CCHFV
in 37 different species of wild birds in South Africa (Shepherd et al.,
1987a), and could not demonstrate viremia in experimentally inoc-
ulated hornbills and starlings, even though H. rufipes larvae feeding
on them became infected (Zeller et al., 1994). The potential role of
migratory birds in the spread of CCHFV to new geographic areas,
through the transport of virus-infected larvae and nymphs, is dis-
cussed below.
4.5. Transmission to humans
Human beings are dead-end hosts for CCHFV. Infections are
usually observed as single, sporadic cases, when people in rural
areas are bitten by virus-infected ticks (Fig. 7). As discussed above,
the disease is seen most commonly in the spring and summer,
when adult stages of Hyalomma and other vector species are seek-
ing the blood meals required for their maturation. An increased
number of cases is often seen following mild winters, which favor
the survival of infected ticks (Estrada-Pena et al., 2012a).
In addition to tick exposure, CCHF can also result from contact
with the blood of infected animals, principally among abattoir
workers. Because the rapid acidification of muscle following death
appears to inactivate the virus, persons who purchase freshly
butchered meat are not at risk of infection. Person-to-person trans-
mission can occur through contact with the virus-containing body
fluids of a patient during the first 7–10 days of illness (Fig. 7). How-
ever, numerous studies have shown that standard barrier nursing
methods are sufficient to prevent the transmission of CCHF in
the patient care setting (Athar et al., 2005; Maltezou et al., 2009).
Asymptomatic infection of health care workers apparently does
not occur (Ergonul et al., 2007). Imported cases of CCHF have
occurred in France (Jaureguiberry et al., 2005) and the United
Kingdom, but without further person-to-person transmission.
5. Geographic range of CCHFV
Since CCHF was first recognized in 1944, the known geographic
distribution of its causative agent has expanded from the Crimea in
the southern Soviet Union to cover a huge area, from western
China across southern Asia to the Middle East, Bulgaria and the Bal-
kans, and throughout most of Africa (Figs. 1 and 2). Most nations
within this region have reported cases of CCHF in humans. In some
countries where the disease has never been diagnosed, evidence of
virus circulation is based on the recovery of viral sequences or live
virus from ticks or from wild or domestic animals, or the detection
of virus-specific antibodies in serosurveys of humans and animals.
The following sections summarize the history of detection of
CCHFV in four geographic regions: western areas of the former So-
viet Union and in southeastern and southwestern Europe; eastern
and central Asia; the Middle East and Turkey; and Africa. Each sec-
tion is accompanied by a table listing the total number of cases of
CCHF for individual countries, with the overall CFR, as reported in
the medical literature (Tables 1–4). The articles from which the
data were obtained are listed in Supplementary Table 1. To desig-
nate the lineages/clades of viruses isolated in various countries, we
utilize both the Roman numeral system of Carroll et al. (2010) and
the geographic naming system of Hewson and co-workers (Atkin-
son et al., 2012b) (Table 7).
5.1. CCHF in western areas of the former Soviet Union and in southern
Europe
5.1.1. The former Soviet Union
The identification of Crimean HF by Chumakov and his col-
leagues in 1944 led to extensive research on the disease at the
Institute of Poliomyelitis and Viral Encephalitis in Moscow. Initial
studies were limited by the inability of investigators to cultivate
the virus, but the discovery in 1967 that the agent could be prop-
agated in suckling mice led to the recovery of numerous isolates,
including the Drozdov strain from a patient in Astrakhan (Chuma-
kov et al., 1968). Since the breakup of the Soviet Union, outbreaks
of CCHF in the territory of the Russian Federation have been de-
scribed only in Russian-language journals (Onishchenko et al.,
2005). The incidence of the disease has clearly been increasing;
from 2002 to 2008, there were more than 1000 confirmed cases,
with a 3.2% mortality rate (Butenko and Karganova, 2007; EpiSouth
and WHO (2008), Leblebicioglu, 2010). Viruses circulating in
southern Russia appear to belong to a single clade (Yashina et al.,
2003a).
5.1.2. Southeastern Europe
Within a few years after the identification of CHF in 1944, a sim-
ilar condition was recognized in Bulgaria, which subsequently be-
came a center for research on the disease. Work in Bulgaria
resulted in the development of a mouse brain-derived CCHF vac-
cine, which has been in use since the early 1970s, and the prepara-
tion of specific immune globulin from hyperimmunized
volunteers, which is banked and utilized for treatment of patients
(see sections on vaccines and therapy below).
Table 7
Designations of genetic lineages/clades of CCHFV, based on analysis of complete or partial sequences of the viral S-segment.
Designation by Carroll et al.
(2010)
Countries where isolated Designation by Atkinson et al.
(2012a, 2012b)
Designation by Mild et al.
(2010)
I Iran, South Africa, Senegal, Mauritania Africa 3 6
II South Africa, Namibia, DRC, Uganda Africa 2 5
III South Africa, Namibia, UAE, Senegal, Mauritania, Nigeria, Burkina
Faso, CAR
Africa 1 3
IV Iran, Pakistan, UAE, Madagascar, Oman, Iraq, China, Uzbekistan,
Kasakhstan, Tadjikistan
Asia 1, Asia 2 1, 2
V Iran, Turkey, Greece, Russia, Bulgaria, Kosovo, Albania Europe 1 4
VI Greece, Turkey Europe 2 7
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More than 1500 cases of CHF/CCHF were diagnosed in Bulgaria
during the period 1953–2008 (Papa et al., 2004). Human infections
are seen principally in the eastern portion of the country in the
spring and summer months, among men engaged in farming and
other work involving tick exposure. Surveys have detected
CCHFV-specific antibodies in livestock where the disease is most
prevalent, and identified CCHFV by RT-PCR in 2% of some 900 ticks
sampled (Gergova et al., 2012). A cluster of cases was recently re-
ported in southwestern Bulgaria, where the disease had not previ-
ously been seen (Christova et al., 2009).
To the south, CCHF is endemic throughout the Balkan states.
Outbreaks were identified in Kosovo in the early 1950s, and cases
continue to be reported (Duh et al., 2008). Virus-specific antibodies
have been detected in some 10–20% of livestock and humans in en-
demic areas (Papa et al., 2002b). In Albania, CCHF was first recog-
nized in 1986, and sporadic cases and outbreaks have occurred
since that time (Papa et al. 2002a).
In Greece, CCHFV was first identified in 1975, through the isola-
tion of the AP92 virus strain from ticks of the species Rhipicephalus
bursa that had been recovered from goats (Papadopoulos and Kop-
topoulos 1978). Despite the detection of anti-CCHFV antibodies in
the local population (Antoniadis and Casals, 1982), no cases of dis-
ease were identified over the subsequent 33 years, leading to the
proposal that the AP92 strain, which diverged markedly in se-
quence from other CCHFV isolates, did not cause illness in humans.
This hypothesis was partially confirmed by the finding that a child
with mild CCHF in the Balkan portion of Turkey in 2007 was in-
fected by an AP92-like virus, and a local serosurvey identified 38
people with IgM antibodies to CCHFV, but no history of illness
(Midilli et al., 2009). The first case of CCHF in Greece was identified
in 2008, in a person living close to the Bulgarian border, who devel-
oped hemorrhagic fever after a tick bite (Papa et al., 2009a). The
virus was closely related to other strains isolated in the Balkans.
A recent nationwide serosurvey revealed significant variation in
the prevalence of anti-CCHFV antibodies, with high levels among
older men in contact with livestock (Sidira et al., 2011).
With the exception of a single human case in Hungary in 2004
(Hornok and Horvath, 2012), CCHF has not been reported in any
country north of Bulgaria. However, adult H. marginatum ticks have
been identified on livestock in Hungary and Romania, indicating
that they are capable of carrying out their entire maturation cycle
in areas further north than was previously thought possible (Ceia-
nu et al., 2012; Hornok and Horvath, 2012). The detection of
CCHFV-specific antibodies in sheep has provided further evidence
of virus circulation in Hungary and Romania.
5.1.3. Southwestern Europe
No indigenous cases of CCHF have been reported in any Euro-
pean country west of the Balkans. Until recently, evidence of virus
activity was limited to the detection of anti-CCHFV antibodies in
bats in France (cited by Hoogstraal (1979)) and in Portugal in the
1980s (Filipe et al., 1985). However, in early 2012, Spanish
researchers reported the detection of CCHFV RNA in H. lusitanicum
ticks recovered fromwild deer (Estrada-Pena et al., 2012c). The iso-
late was most closely related to African strains, suggesting that it
might have been introduced by migratory birds.
5.2. CCHF in eastern and central Asia
An outbreak of HF that occurred in western China in 1965 was
retrospectively identified as CCHF by testing samples from hu-
mans, sheep and ticks (Yen et al., 1985). The virus was first isolated
from Hyalomma ticks in Pakistan in the 1960s (Begum et al., 1970),
and repeated outbreaks and sporadic cases have been seen since
that time, especially in persons handling or slaughtering livestock
(Jamil et al., 2005). In early 2011, the first cases of CCHF were
identified in India, in a nosocomial outbreak in Gujarat state, which
adjoins Pakistan (Mishra et al., 2011). A recent serosurvey and
sampling of H. anatolicum ticks showed that infection was present
in local livestock (Mourya et al., 2012).
5.3. CCHF in the Middle East and Turkey
5.3.1. The Middle East
The presence of CCHFV in Iran was first demonstrated in the
1970s, when specific antibodies were found in the sera of humans,
cattle and sheep (Saidi et al., 1975); viral antigen was detected in
sheep in an abattoir in Teheran (Hoogstraal, 1979); and viruses
were isolated from ixodid ticks (Sureau and Klein, 1980). Cases in
humans were first observed in 1999, and have since been reported
in most provinces (Chinikar et al., 2004; Chinikar et al., 2010). In
neighboring Iraq, surveillance was interrupted by civil unrest and
war for nearly a decade, but a number of cases of CCHF have re-
cently been reported (Majeed et al., 2012). Following an outbreak
of some 60 cases in Herat, Afghanistan, in 2009, a serosurvey found
high levels of specific IgG in cattle and sheep in the surrounding
area (Mustafa et al., 2009).
CCHF was first detected in the Arabian Peninsula in a hospital
outbreak in 1979 in Dubai (Suleiman et al., 1980). Additional cases
were not seen until 1994, when an epidemic occurred among abat-
toir workers in the United Arab Emirates (Khan et al., 1997). A
serosurvey performed as part of the investigation found that many
livestock animals raised in the region had antibodies to CCHFV,
while imported animals were negative. Human infections were
identified in Oman in the mid-1990s, and a subsequent survey of
livestock and ticks confirmed the local circulation of the virus
(Scrimgeour, 1996; Williams et al., 2000)
5.3.2. Turkey
Turkey represents a special case in CCHF epidemiology, as the
past decade has seen its transformation from a country free of hu-
man infections to the ‘‘epicenter’’ of the disease, with more than
1000 confirmed cases per year. It is likely that CCHF has long been
present, but unrecognized, but the surge in human infections may
also reflect an environmental situation similar to that which oc-
curred in the Crimea at the end of World War II, in which the reoc-
cupation of abandoned agricultural lands resulted in a marked
increase in tick exposure.
The first case of CCHF was identified in Turkey in 2002 (Karti
et al., 2004), in patients in the eastern Black Sea region. As of
2009, nearly 5000 infections had been diagnosed, with a mean
fatality rate of approximately 5% (Ozkaya et al., 2010). Because
the early signs and symptoms of the disease are nonspecific, some
2/3 of CCHF patients are initially misdiagnosed (Tasdelen Fisgin
et al., 2010). Most cases occur in the Anatolian plateau region of
central and eastern Turkey, where a serosurvey detected specific
antibodies in almost 80% of domestic animals (Gunes et al.,
2009), and virus was isolated from some 20% of Hyalomma ticks
(Gunes et al., 2011). A recent serosurvey of more than 3500 resi-
dents of this hyperendemic area found a 10% positivity rate, indi-
cating the occurrence of numerous subclinical infections (Bodur
et al., 2012). Older age, farming and a history of tick bites were risk
factors for seropositivity.
Almost all viruses isolated from humans or ticks in the Anato-
lian region belong to European clades (see below) (Ozkaya et al.,
2010). In cases in western Turkey, a survey identified RNA from
viral clades Europe 1 and Europe 2 in H. marginatum and R. bursa
ticks, and a 10% prevalence of anti-CCHFV IgG in the local popula-
tion (Gargili et al., 2011). However, a case of mild illness in the
European portion of the country in 2009 was caused by a virus clo-
sely related to the Greek AP92 strain (Midilli et al., 2009).
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5.4. CCHF in Africa
As noted above, CCHF was first identified in Africa in 1967,
when the virus was isolated by suckling mouse brain passage from
a blood sample collected 11 years earlier from a young boy in the
Belgian Congo (Simpson et al., 1967; Woodall et al., 1967); the
agent was later shown to be identical to CHFV (Casals, 1969). Over
the next few years, this ‘‘Congo virus’’ was also recovered from pa-
tient blood specimens, serum samples from domestic goats and
cattle and from various species of Hyalomma ticks in Uganda and
Nigeria (Causey et al., 1970). Analysis of virus recovered from a re-
cent case in the DRC indicates that the same strain continues to cir-
culate (Grard et al., 2011).
The majority of CCHF cases in Africa have been reported from
South Africa, where the first case was identified in 1981, when a
boy who returned from camping with a Hyalomma tick on his scalp
died of hemorrhagic fever (Gear et al., 1982). In 1985, a cluster of
cases was seen in farmers and other persons exposed to cattle and
sheep,many ofwhom reported recent tick bites; an ensuing nosoco-
mial outbreak at Tygerberg Hospital permitted detailed study of the
disease (van Eeden et al., 1985a; Joubert et al., 1985; van Eeden
et al., 1985b). Cases that occurred about the same time in ostrich
workers are described below. By 1989, Swanepoel and his col-
leagues were able to review clinical pathologic findings in 50 CCHF
patients treated in South African hospitals (Swanepoel et al., 1989).
Ecological studies have shown that CCHFV circulates among a
variety of wild and domestic animals in South Africa. An analysis
of nearly 4000 serum samples from 87 species demonstrated the
presence of anti-CCHFV antibodies in scrub hares and in buffalo
and other large animals, suggesting that the virus is maintained
among wild vertebrates and ‘‘spills over’’ into domestic animals
(Shepherd et al., 1987b). On the dairy farm where the 1985 out-
break occurred, many cattle were positive for anti-CCHFV antibod-
ies (Swanepoel et al., 1985). While nearly 30% of cattle were
seropositive in regions where Hyalomma ticks were present, few
positives were detected in coastal areas, where that tick species
was not observed (Swanepoel et al., 1987). A later study found that
the prevalence of antibody-positive sheep was highest on farms
where human infections had occurred (Fisher-Hoch et al., 1992).
A unique feature of CCHF in South Africa is the occurrence of the
disease in workers on ostrich farms, through exposure to ticks
while slaughtering and skinning the birds (van Eeden et al.,
1985a) (Swanepoel et al., 1998). A survey found that about one-
fourth of ostriches in farms where CCHF was seen had antibodies
to CCHFV, but none of some 500 other birds showed evidence of
virus exposure (Shepherd et al., 1987a). Experimental infection
showed that ostriches develop several days of viremia of suffi-
ciently high titer to infect ticks. The hazard to humans who handle
ostriches has been reduced through the use of acaricides and the
imposition of a 30-day quarantine before slaughter.
CCHFV also circulates in Sudan, as indicated by the detection of
seropositive livestock, the occurrence of sporadic human cases and
a recent nosocomial outbreak (Aradaib et al., 2011). In Kenya, the
virus has been identified by RT-PCR in Hyalomma ticks collected
from livestock, and antibodies were detected in local residents
(Lwande et al., 2012; Sang et al., 2011). Reports published during
the past decade of cases or outbreaks in Mauritania and Senegal in-
clude summaries of earlier studies of the circulation of CCHFV in
those and other African countries (Nabeth et al., 2004a) (Nabeth
et al., 2004b).
6. Genetic diversity of CCHFV
As a means of studying the evolutionary history of CCHFV and
the mechanisms responsible for its marked degree of sequence
diversity, a number of research groups have generated phyloge-
netic trees of the S-, M- and L-segments of the viral genome. Such
trees have often been based on partial or complete sequences of
the S-segment, because the largest number of sequences have been
archived. However, the most informative phylogenetic analyses
have made use of the more limited number of complete S-, M-
and L-gene sequences that are available in GenBank.
To create up-to-date phylogenetic trees for this paper, we uti-
lized 52 full-length S-segment, 35 M-segment and 30 L-segment
sequences (for methods, see the legend of Fig. 8). Because trees
generated using ML and Bayesian algorithms exhibited the same
topology, only the ML trees are shown (Figs. 8–10). Within each
of the trees, we identified six separate viral lineages or clades orig-
inating from the same branch points, indicating that their mem-
bers share a common ancestor. We have labeled these clades I–
VI, using the system employed by some other investigators (Carroll
et al., 2010). As shown in Table 7, other researchers have identified
7, rather than 6 virus lineages, and have utilized a different labeling
system. However, this apparent disagreement seems to reflect dif-
fering perceptions of the relationships among closely-related
branches, rather than an actual difference in the structures of phy-
logenetic trees.
As noted above, CCHFV displays the greatest degree of sequence
diversity of any arbovirus, with divergence of 20, 22 and 31%
among the S-, L- and M-segments of virus isolates. This marked
variation, reflected in the breadth of the phylogenetic trees, can
be attributed to the progressive accumulation of copying errors
by the RNA-dependent RNA-polymerase (RdRp) (genetic ‘‘drift’’).
Analysis of the phylogenetic trees shown in Figs. 8–10 also reveals
evidence of the following:
 the existence of discrete lineages or clades of viruses that share
a common ancestor, most (but not all) of which were isolated in
the same geographic region;
 the occurrence of long-distance virus transfer, as shown by the
presence within the same clade of viruses isolated in widely dis-
tant locations;
 the occurrence of genetic reassortment, as shown by the non-
homologous locations of the S, M and L segments of some
viruses within their respective phylogenetic trees, indicating
that the segments have different evolutionary histories;
 the occurrence of genetic recombination, resulting in more sub-
tle differences in the location of individual viruses within phy-
logenetic trees, reflecting the abrupt sequence discontinuities
found when genome segments are aligned.
These 5 processes have all contributed to the present genetic
diversity of CCHFV; each will now be discussed in turn.
6.1. Genetic drift
Sequence changes introduced by the error-prone RdRp have
provided the underlying diversity required for natural selection
to shape the evolution of CCHFV, facilitating its adaptation to many
different tick and vertebrate hosts. Its broad genetic diversity con-
trasts with the much closer sequence homology of other arbovirus-
es, such as Rift Valley fever virus, whose evolution appears to have
been more constrained by the requirement to replicate in a few
vertebrate and mosquito species (Weaver, 2006). The extensive se-
quence diversity of CCHFV may increase the likelihood that strains
introduced into new geographic regions will be able to circulate in
local ticks and infect local vertebrates. Future research should
therefore examine the vector competence of ticks in regions poten-
tially threatened by the geographic spread of CCHFV.
The greater genetic diversity of the CCHFV M segment, com-
pared to the S- and L-segments, reflects the critical role the GN
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and GC glycoproteins in the viral life cycle. Because they are
responsible for binding to cell-surface receptors, underlying
diversity in the sequence of these proteins facilitates the infection
by CCHFV of many different tick and vertebrate hosts. Recent ef-
forts to determine whether M segment sequence diversity is
greater in viruses recovered from vertebrates or from ticks have
been inconclusive (Ozkaya et al., 2010). Within the M segment,
the greatest degree of diversity is seen in the region encoding
the glycoprotein mucin-like domain, while regions encoding por-
tions of protein structure involved in intracellular processing and
maturation are more highly conserved (Papa et al., 2002c; Vincent
et al., 2003).
Interestingly, even though GN and GC show a high level of diver-
sity at the nucleotide level, this does not appear to translate to
greater antigenic diversity. There in fact appears to be little varia-
tion in antigenic sites among CCHF viruses, which form a single
antigenic group, by which they are distinguished from other nairo-
viruses, such as HAZV (Buckley, 1974; Foulke et al., 1981). More
subtle antigenic difference within the CCHFV group have been de-
fined using monoclonal antibodies (Ahmed et al., 2005), but it is
unclear how such variation affects cross-protection among viruses
in vertebrate hosts. Improved understanding of cross-protection
among CCHFV strains is needed for vaccine development; such
data may be difficult to derive from naturally occurring infections
of humans or animals, but could potentially be obtained through
studies in recently developed mouse models of CCHF (see below).
In contrast to the M segment, the L segment shows a much
greater degree of sequence conservation, with up to 90% amino
acid identity across strains (Deyde et al., 2006; Kinsella et al.,
2004; Meissner et al., 2006a). This analysis indicates that the seg-
ment has evolved more slowly, and shows a correspondingly long-
er time to the most recent common ancestor, than the S- and M-
segments (Carroll et al., 2010). Such reduced variation presumably
reflects essential requirements for the efficient function of the
RdRp. However, closer analysis of the L gene has revealed a region
of enhanced variability from amino acid positions 760–810, which
shares only 40% sequence identity among CCHFV strains se-
quenced to date. The existence of this variable region has been
Fig. 8. Phylogenetic tree showing the genetic relationships of the small (S) segment of CCHFV. This tree and those in Figs. 9 and 10 were generated using maximum likelihood
methods calculated using PAUP⁄ version 4.0, 10b. All trees used the same model (GTR + C), which was determined using MODELTEST 3.06, and the variable parameters were
estimated from the data. Bootstrap values (shown only on the major branches, for clarity) were estimated using GARLI with the same parameters using 1000 replicates. Both
Maximum Likelihood and Bayesian trees (data not shown) were congruent for all three trees. Strains highlighted in green show evidence of recombination and strains
highlighted in red show evidence of reassortment.
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exploited for phylogenetic analysis (Meissner et al., 2006a; Meiss-
ner et al., 2006b).
Three research groups have used sequence data to estimate the
rate at which CCHFV is evolving over time (Anagnostou and Papa,
2009; Carroll et al., 2010; Chen, 2012). Both found that the three
genome segments undergo roughly 104 changes per nucleotide
per year, or about two base changes per year for the entire genome.
Carroll et al. observed that the rate of evolution of CCHFV was
somewhat slower than that reported for the mosquito-borne bun-
yavirus, Rift Valley fever virus and the tick-borne flavivirus, Kyasa-
nur Forest disease virus (Bird et al., 2008; Mehla et al., 2009), but
the differences were modest. Because the evolutionary rate of a
virus is simply a way of measuring its genetic diversity, both
groups reported that the CCHFV M segment was evolving more
rapidly than the S or L segment. A more recent paper investigated
whether the presence of reassortant viruses influenced the calcu-
lated evolutionary rates, and concluded that this resulted in some
inherent bias (Chen, 2012); this finding should be confirmed using
a larger dataset. Based on their data, Carroll et al. concluded that
current CCHF viruses have evolved from an ancestral agent that ex-
isted roughly 3000 years ago, and suggested that the spread of live-
stock farming may have contributed to its geographic dispersion.
To date, no studies have focused on the extent of genetic diver-
sity among the population of viruses infecting a single tick or
vertebrate host. Factors that might influence such diversity for
tick-borne viruses might include a low level of viral replication
within the tick, resulting in a smaller population, or bottlenecks
created by transstadial and vertical transmission. CCHFV popula-
tion diversity might also be affected by the occurrence of co-feed-
ing transmission, which would reduce the need for viral replication
in vertebrate hosts (Ebel and Kramer, 2004; Labuda et al., 1994).
6.2. Formation of discrete genetic lineages
As discussed above, phylogenetic analysis has revealed the exis-
tence of some 6 or 7 discrete CCHFV lineages or clades; the labels
assigned to these clades by various investigators are listed in Ta-
ble 7 (Anagnostou and Papa, 2009; Burt and Swanepoel, 2005;
Deyde et al., 2006; Duh et al., 2008; Hewson et al., 2004a; Meissner
et al., 2006a; Morikawa et al., 2002; Yashina et al., 2003a; Yashina
et al., 2003b). The existence of such clades appears to reflect the
fact that CCHFV is not found across a single homogenous geo-
graphic region, but circulates in multiple areas that are separated
from each other to varying degrees by topographic barriers. Differ-
ences of climate, vegetation and other conditions among these
areas have led to the evolution of distinct species of ticks and ver-
tebrates, and the progressive adaptation of CCHFV to these region-
specific hosts has led to the emergence of local virus variants. This
pattern is most visible in the overlapping distribution of virus
clades and various Hyalomma species, consistent with a lengthy
Fig. 9. Phylogenetic tree showing the genetic relationship of CCHFV medium (M) segments. For methods and color coding, see legend of Fig. 8.
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history of co-evolution of the virus with its tick vectors. A similar
pattern has been observed for tick-borne flaviviruses (Lobo et al.,
2009). The relative regional homogeneity of CCHFV has been dem-
onstrated in Turkey by a systematic sampling of local isolates,
which showed little genetic diversity and no evidence of ‘‘invasion’’
by strains from other regions, suggesting that the marked increase
in CCHF that has occurred in Turkey over the past decade has been
caused by viruses indigenous to the country (Kalaycioglu et al.,
2012).
In an attempt to understand the relationship between the evo-
lution over time and geographic distribution of the various
clades/lineages of CCHFV, we have superimposed phylogenetic
trees of the three viral genome segments onto maps, collapsing
each clade into a single node and locating each clade on the
map, based on the geographic location of most or all of its mem-
ber viruses (Figs. 11–13). The phylogeography of the S-segment is
shown in Fig. 11. When the S-segment tree is presented as a tra-
ditional phylogram, with midpoint rooting, the Greek (clade VI)
and West African isolates (clade I) form the root (Fig. 3 and inset).
When superimposed on a map, the pattern of branching of clades
over their evolutionary history appears to indicate a gradual
movement of the virus out of Africa into Europe, then the Middle
East and finally to Asia.
The phylogeography of the CCHFV M-segment appears to show
the same pattern as the S-segment, with the root (as defined by
midpoint rooting) being the Greek (VI) and W. Africa (I) strains
(Fig. 12). The reassortant Chinese strain is indicated; for the sake
of clarity, other reassortant viruses highlighted in green in Fig. 8
are not shown on the map. The branching pattern of the superim-
posed M-segment tree also appears to show a progression of the
virus out of Africa, but with Europe/Turkey appearing to be a later
lineage, compared to the map of the S-segment. In contrast, the L
segment shows a very different phylogeography (Fig. 13). While
groups (VI) and (II) are basal to the tree, as defined by midpoint
rooting, the Asian strains appear to be older than the Europe/Tur-
key, South Africa and West Africa II strains. As defined by the phy-
lograms (Figs. 8–10), the Greek AP andWest African viruses are the
oldest lineages, suggesting that CCHFV originated in the European/
African area, probably within the Mediterranean basin. Many more
sequences of viruses isolated across the broad geographic range of
CCHFV will be required to obtain a clear understanding of its evo-
lutionary history.
Fig. 10. Phylogenetic tree showing the genetic relationship of CCHFV large (L) segments. For methods and color coding, see legend of Fig. 8.
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The adaptation of CCHFV to region-specific hosts, leading to
clade formation, could potentially result in differences in its path-
ogenicity for humans. Careful clinical studies will be required to
determine whether viruses with different levels of virulence actu-
ally exist. This is well illustrated by the history of the AP92 strain,
which was recovered from Rhipicephalus ticks in Greece in 1978
(Papadopoulos and Koptopoulos, 1978), and which differs suffi-
ciently in sequence from other strains to constitute its own clade
(Fig. 3). Because no similar viruses were recovered from patients
during subsequent decades, the AP92 strain was thought to be
avirulent for humans. However, investigators recently recovered
closely related agents from patients with mild CCHF in the Euro-
pean portion of Turkey (Elevli et al., 2010; Midilli et al., 2009; Oz-
kaya et al., 2010). Although the source of infection was not
identified, a survey of local tick species revealed that, in addition
to Hyalomma, some 30% were R. bursa. If further investigation con-
firms that the AP92 virus is less virulent for humans than other
strains, it will be of interest to determine if it is maintained exclu-
sively in Rhipicephalus ticks.
6.3. Evidence of long-distance virus transport
Examination of the phylogenetic trees in Figs. 3–5 and of the
geographic origin of viruses in individual clades (Table 7) shows
that several clades contain members from widely distant regions.
The geographic separation of viruses with closely related
sequences indicates that, although some areas in which CCHF is
endemic are separated from each other by topographic barriers,
they have apparently been connected through the long-distance
transfer of infected ticks, which has made it possible for a strain
of CCHFV to leave its ‘‘ancestral home’’ and become established
in a new area. The possibility that a vertebrate host might be
simultaneously infected by both a local and a newly introduced
virus, and that such viruses might be exchanged among ticks dur-
ing co-feeding, increases the potential for reassortment and recom-
bination to serve as mechanisms of CCHFV evolution (see below).
The long-distance transfer of CCHF viruses could occur through
at least two different mechanisms (Mild et al., 2010). The first,
which has presumably taken place for millennia, is the transport
of infected ticks by migratory birds. As noted above, with the
exception of ostriches, there is no evidence that birds are hosts
for the replication of CCHFV (Shepherd et al., 1987a). However,
many competent tick vectors of CCHFV feed on birds during their
larval and nymph stages, and could potentially be carried great dis-
tances, should they attach to a bird before it sets off on its
migration.
The second possible mechanism of long-distance virus transfer,
which has begun relatively recently on the biological time-scale, is
the international shipment of livestock, which can introduce in-
fected animals and ticks into areas previously free of disease, or
add novel virus strains in regions where CCHFV already circulates.
The spread of virus by human migration and trade is a likely
Fig. 11. Stylized representation of the phylogenetic relationships of the CCHFV S segment, overlaid on geographic areas in which viruses of the different genetic groups were
isolated. The branch lengths do not reflect genetic diversity, but are distorted to reflect geographic distance. The inset shows the phylogenetic tree of the S segment, in its
standard presentation.
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scenario, based on the recent finding that the CCHFV S and the M
segments both originated approximately 3000–3500 years ago
(Carroll et al., 2010). Interestingly, the investigators found that cur-
rently existing L segments pre-dated them, sharing a common
ancestor some 7000 years before the present. This disparity was re-
solved if the Greek AP92 strain was eliminated from the analysis,
suggesting that the L segment of that virus resulted from reassort-
ment with another, unidentified virus. The recovery and sequenc-
ing of are large number of CCHFV isolates from many areas will
be needed to provide a reliable history of its geographic origin
and long-distance transport.
6.4. Evidence of genetic reassortment
As discussed above, the movement of CCHFV-infected ticks or
livestock between geographic regions makes it possible for a verte-
brate or tick to be simultaneously infected by two virus strains
with different evolutionary histories. Because the virus has a tri-
segmented genome, co-infection can potentially generate viruses
with novel S, M and L segment combinations {Burt, 2009 #99;
Hewson, 2004 #8; Chen, 2013 #43}. Because replication in mam-
mals is relatively brief, while ticks remain infected throughout
their several-year lifetimes, and may accumulate multiple strains
of CCHFV during repeated rounds of blood feeding, co-infection
of cells by two viruses is more likely to occur in ticks than in ver-
tebrates (Davies et al., 1987; Jones et al., 1987a).
The occurrence of reassortment is easiest to recognize when the
two parental viruses are genetically diverse, such that their S, M
and L segments are located in different clades, or occupy different
relative positions within the same clade. For CCHFV, evidence of
reassortment is seen most frequently as an anomaly in the position
of the M segment, while the S and L segments occupy similar posi-
tions within their phylogenetic trees (Chamberlain et al., 2005).
Several viruses showing evidence of such M-segment reassortment
are highlighted in green in Figs. 3–5. This tendency of the S and L
segments to remain together suggests that virus with a NP and
RdRp that have evolved together will replicate more efficiently
than one in which those proteins have separate evolutionary histo-
ries, while variation in GN and GC has less effect (Chamberlain et al.,
2005).
Although co-infection of a tick or vertebrate by differing CCHFV
strains has presumably occurred throughout the history the virus,
the development of distinct viral clades has increased the impor-
tance of genetic reassortment as an evolutionary mechanism, as
progeny viruses may potentially display novel phenotypes, includ-
ing an altered capacity for transmission among ticks and verte-
brates and reduced or increased virulence for humans. Studies of
another bunyavirus, Ngari virus, have shown that reassortment
Fig. 12. Stylized representation of the phylogenetic relationships of the CCHFV M segment, overlaid on geographic areas in which viruses of the different genetic groups were
isolated. The branch lengths do not reflect genetic diversity, but are distorted to reflect geographic distance. Most CCHFV strains showing evidence of M segment
reassortment, as highlighted in Figs. 8–10, have been excluded.
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can result in changes in virulence (Briese et al., 2004). In the only
study that has attempted to assess such differences for CCHFV, Burt
and colleagues observed a higher mortality rate among South Afri-
can patients infected by viruses whose M segments mapped to
Asian clades (Burt et al., 2009).
6.5. Evidence of genetic recombination
Alignment of the genome segments of some CCHF viruses has
revealed points of abrupt discontinuity, consistent with a history
of strand exchange through recombination (Hewson et al., 2004a;
Lukashev, 2005). Bootscan analysis has shown the clearest evi-
dence of recombination in the S segment (Lukashev, 2005). The
data suggest that genetic exchanges were rare events, and that
strand exchanges had not occurred during the recent history of
the virus. Potential recombinant strains identified by Carroll et al.
(2010) are highlighted in red in Figs. 8–10.
7. Clinical and laboratory features of CCHF
7.1. Clinical features
Although many infections with CCHFV result in a mild, nonspe-
cific febrile illness, some patients develop severe hemorrhagic
disease. In the 1944 Crimean outbreak, hospitalized patients
showed a sudden onset of fever, accompanied by weakness, head-
ache and muscular pains, vomiting, marked hyperemia of the face
and oropharynx, a hemorrhagic rash with development of ecchy-
moses and bleeding from the nasopharynx, gastrointestinal tract
and other sites (Grashchenkov, 1945). Similar findings were re-
ported in case series and outbreak reports from South Africa, Tur-
key and Kosovo (Swanepoel et al., 1989; Ergonul, 2006).
As summarized by Hoogstraal (1979), the course of CCHF can be
divided into four phases: incubation, prehemorrhagic, hemorrhagic
and convalescent. The length of the incubation period appears to
depend in part on the mode of acquisition of virus. Following a tick
bite, it ranges from 1–5 days, while it is usually 5–7 days following
contact with infected blood or tissues, with a maximum of 13 days
(Ergonul, 2006; Ergonul et al., 2006c). It has been suggested that
immunological effects of substances in tick saliva play a role in
accelerating viral dissemination (Jones et al., 1992; Kocakova
et al., 1999; Nuttall and Labuda, 2004).
The prehemorrhagic phase of CCHF is characterized by fever,
lassitude and a variety of nonspecific signs and symptoms; clini-
cians aware of an appropriate exposure history may make a diag-
nosis by RT-PCR. The hemorrhagic phase typically begins on day
3–5 of illness (Ergonul, 2006). Its most common initial manifesta-
tion is a petechial rash of the skin, conjunctiva and other mucous
membranes, which progresses to large cutaneous ecchymoses
Fig. 13. Stylized representation of the phylogenetic relationships of the CCHFV L segment, overlaid on geographic areas in which viruses of the different genetic groups were
isolated. The branch lengths do not reflect genetic diversity, but are distorted to reflect geographic distance.
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(Fig. 7) and bleeding from the gastrointestinal and urinary tracts
(Swanepoel et al., 1989). Hepato- and splenomegally are common.
In fatal cases, death generally occurs on day 5–14, as a result of
hemorrhage, multi-organ failure and shock. Cerebral hemorrhage
may occur, as well as bleeding from the vagina and the abdominal
musculature.
In patients who survive CCHF, full recovery may take up to a
year (Ergonul, 2006). An early report from South Africa noted that
recovering patients often experienced a variety of health problems,
including weakness, hair loss, poor appetite, polyneuritis, hearing
loss, impaired memory and vision and hepatorenal insufficiency
(Swanepoel et al., 1989). However, more recent articles from Tur-
key and Iran have not described such problems (Bakir et al.,
2005; Mardani and Keshtkar-Jahromi, 2007). There has been no
documented relapse of infection.
7.2. Clinical laboratory findings
Common abnormalities of CCHF patients in standard hospital
laboratory tests were described by Swanepoel et al. (1989) and
summarized more recently by Ergonul (2008). Hematology testing
shows an early leukopenia, with the development of thrombocyto-
penia during the first week of illness; platelet counts may be extre-
mely low in fatal cases. A fall in the hemoglobin level is also typical
of severe disease. At the same time, coagulation abnormalities de-
velop, with prolongation of the prothrombin time (PT) and acti-
vated partial thromboplastin time (aPTT), and detection of fibrin
degradation products and D-dimers, indicative of disseminated
intravascular coagulation (DIC). Progressive hepatic involvement
results in increased levels of liver-associated enzymes, alanine
and aspartate aminotransferase (ALT and AST), in the serum. As pa-
tients become hypotensive, increased blood urea nitrogen (BUN)
and creatinine provide a measure of renal insufficiency.
7.3. Case fatality rate
As noted above, the reported CFR of CCHF has varied widely,
with the percentage of fatal cases in some small series exceeding
30% (see Supplementary Table 1). However, the often small sam-
ples size of outbreaks and the lack of diagnostic capabilities make
it difficult to ensure that all patients with mild illness have been
detected and included in the denominator. However, the average
CFR for the more than 6000 cases that have occurred in Turkey
over the past decade has been approximately 5%, suggesting that
the higher rates reported in earlier outbreaks reflect a failure to
recognize less severe infections. Despite such observational bias,
it is possible that variation in the CFR at different times and places
reflects either the quality of medical care and treatment or differ-
ences in virulence of circulating CCHFV strains.
7.4. Predictors of survival or death
Early identification of severely ill CCHF patients is important,
both to ensure that they receive optimal care and to identify those
with the highest viral loads, who pose the greatest hazard to health
care workers. Experience over the past decade in Turkey has shown
that gingival bleeding, ecchymoses, hematemesis, diarrhea, mele-
na, confusion and somnolence are significantly more common in
fatal cases (Ergonul et al., 2006a; Cevik et al., 2008; Hatipoglu
et al., 2010). Lethal illness was associated with more severe throm-
bocytopenia, more prolonged PT and aPTT, lower fibrinogen levels
and increased serum AST and ALT (Ergonul et al., 2006a; Ozkurt
et al., 2006; Onguru et al., 2010). Serum levels of neopterin, a deriv-
ative of GTP released by activated macrophages, were higher in
fatal than nonfatal cases of CCHF (Onguru et al., 2008). A scoring
system for CCHF severity, based on a combination of the patient’s
age and underlying health status and the clinical and laboratory
findings on the day of hospital admission, has recently been pro-
posed (Bakir et al., 2012).
Fatal cases of CCHF reflect the inability of the immune system to
control infection, as reflected in weak or absent antibody re-
sponses, high titers of circulating virus and markedly elevated ser-
um cytokine levels. Early studies in South Africa found that most
patients who went onto survive the disease had detectable anti-
CCHFV IgM by day 7 and IgG by day 7–9 of illness, while no re-
sponse was detected in fatally infected individuals (Burt et al.,
1994; Shepherd et al., 1989c; van Eeden et al., 1985b). The correla-
tion of antibody responses with survival has been demonstrated
more recently in patients in Turkey and Kosovo (Ergonul et al.,
2006a; Saksida et al., 2010).
Failure to control viral replication results in elevated serum
virus titers (‘‘viral load’’) and more intense systemic inflammatory
responses. For example, a study of 36 patients in Turkey found that
8 of 9 fatal cases had peak serum virus levels >109 viral genome
copies/mL, whereas the peak levels of 25 of 26 survivors were be-
low that level (Cevik et al., 2007). Similar observations have been
made in Kosovo and Albania (Duh et al., 2007; Papa et al., 2006).
Studies in both countries have shown that serum viral load is di-
rectly related to disease severity (Ergonul et al., 2006b; Saksida
et al., 2010). In Kosovo, fatally infected patients had the highest
levels of TNF-a, IFN-c and IL-10, while the Turkish study found
that fatality was correlated with elevated IL-6 and TNF-a, but not
IL-10.
8. Diagnosis
CCHF should be suspected when a person with an appropriate
exposure history becomes acutely ill with fever, malaise and other
nonspecific signs and symptoms, together with physical findings
suggestive of vascular leak and coagulation defects. Suspicion is
strengthened if the initial laboratory evaluation shows leukopenia,
thrombocytopenia and elevated serum AST and ALT levels. A spe-
cific diagnosis may be made by testing a serum specimen for viral
RNA by RT-PCR and for virus-specific IgM and/or IgG by ELISA or
other methods. The recovery of infectious virus was long consid-
ered the ‘‘gold standard’’ for diagnosis, but it requires Biosafety Le-
vel 4 containment, which is not available in any CCHF-endemic
country except for South Africa. In view of its speed, sensitivity
and safety, RT-PCR should now be considered the standard diag-
nostic method.
CCHF patients are usually viremic during the first 7–10 days of
illness. Virus-specific IgM becomes detectable by the end of the
first week, with IgG appearing shortly thereafter. Clinicians caring
for an acutely ill patient should therefore test for viral RNA and for
IgM, if both assays are available. However, because severely ill pa-
tients may fail to develop an antibody response, RT-PCR is the most
reliable diagnostic method; by measuring viral load, it also pro-
vides an index of disease severity and the likelihood of death.
Virus-specific IgM clears after several months, while IgG persists
much longer. The presence of anti-CCHFV IgG in a person with
an appropriate illness history may therefore be used to make a ret-
rospective diagnosis.
A number of recent articles have reviewed diagnostic tech-
niques for CCHF or assessed their sensitivity and accuracy. Current
laboratory assays and commercially available kits are listed by
Mertens et al. (2013). Dowall et al. (2012b) have described a novel
ELISA method, based on recombinant viral NP that was able to sen-
sitively detect virus-specific IgM and IgG in patient samples from
Turkey, Tadjikistan and Kosovo. An international quality assess-
ment of conventional and real-time RT-PCR assays for CCHFV
found that nearly half of the 44 participating laboratories
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performed suboptimally on a panel of samples (Escadafal et al.,
2012). A comparison of several commercially available IFA, ELISA
and RT-PCR kits found them all to have excellent specificity, but
their sensitivities were generally less than 90% (Vanhomwegen
et al., 2012).
Concerns that sequence-based diagnostic assays may not detect
all strains of CCHFV are based on its wide genetic diversity.
Although the first RT-PCR assays could identify viruses from most
clades or geographic regions (Duh et al., 2006; Garrison et al.,
2007; Wolfel et al., 2007), they were unable to recognize the highly
divergent AP92 strain. However, a recently reported assay target-
ing a highly conserved portion of the 50-noncoding region of the
viral S segment, which is apparently required for ‘‘panhandle’’ for-
mation and genome replication, is able to detect viruses in all 7
clades, including AP92 (Atkinson et al., 2012a). As more specimens
are obtained from humans, animals and ticks throughout endemic
regions, and as the virus continues to evolve over time, further
refinements in sequence-based diagnostic methods may be
needed.
9. Therapy
9.1. General supportive measures
Most CCHFV infections are either asymptomatic or result in a
nonspecific febrile illness that does not require hospitalization or
specific therapy. In the small percentage of patients who develop
hypotension and hemorrhage, current medical management is lar-
gely supportive. The fall in blood pressure and diminished organ
perfusion that result from increased vascular permeability call
for volume replacement, usually with intravenous fluids, with
careful monitoring to prevent the development of pulmonary ede-
ma. Coagulation abnormalities may be countered through the pro-
vision of fresh frozen plasma and platelets, while the occurrence of
significant hemorrhage will require blood transfusion. Several re-
cent articles by clinicians experienced with the therapy of CCHF
provide advice and algorithms for the treatment of adult and pedi-
atric patients (Ergonul, 2008; Leblebicioglu et al., 2012; Mardani
et al., 2010). A recent report from Turkey suggested that a combi-
nation of high-dose methylprednisolone, intravenous immuno-
globulin and fresh-frozen plasma was beneficial, but the authors
did not include a control group (Erduran et al., 2012).
9.2. Ribavirin
Ribavirin, a guanosine analogue licensed for the treatment of
respiratory syncytial virus infections and hepatitis C, has been used
to treat CCHF patients for more than two decades. Inhibition of
CCHFV replication has been demonstrated in a minigenome system
(Bergeron et al., 2010), in virus-infected cells (Huggins, 1989;
Watts et al., 1989; Paragas et al., 2004), in newborn mice (Tignor
and Hanham, 1993) and in STAT-1 KO mice (Bente et al., 2010).
Comparisons of a number of virus strains found that they differed
no more than a few-fold in sensitivity to the drug (Watts et al.,
1989; Paragas et al., 2004).
The use of ribavirin for the treatment of CCHF has been re-
viewed in detail in two recent articles (Soares-Weiser et al.,
2010; Keshtkar-Jahromi et al., 2011). The drug was first employed
in 1985, when it was given as postexposure prophylaxis in a noso-
comial outbreak in South Africa (van de Wal et al., 1985). Ten years
later, 3 CCHF patients in Pakistan were treated with ribavirin and
appeared to respond rapidly to therapy (Fisher-Hoch et al., 1995).
Apparently beneficial results were subsequently described in
observational studies from Iran and Turkey, which lacked control
groups (Smego et al., 2004; Jabbari et al., 2006; Midilli et al., 2007).
As the increased numbers of CCHF patients seen during the past
decade have made larger comparisons possible, investigators have
generally found that ribavirin is beneficial, so long as it is initiated
early in the course of illness (Mardani et al., 2003; Ergonul et al.,
2004; Alavi-Naini et al., 2006). (Tasdelen Fisgin et al., 2009). How-
ever, a recent attempt to identify a benefit of ribavirin in a random-
ized clinical trial was unable to show that treatment significantly
altered the disease (Koksal et al., 2010). A review of 21 published
observational and experimental studies of ribavirin therapy con-
cluded that, although most reports claimed a therapeutic benefit,
the quality of the evidence was low (Soares-Weiser et al., 2010).
The authors concluded that ‘‘a randomized controlled trial in the
context of good quality supportive care is justified.’’ No report
has described any serious adverse effects of ribavirin therapy.
9.3. Antibody therapy
Anti-CCHF immune globulin, prepared from the plasma of dis-
ease survivors, was recommended as therapy by Chumakov at
the time of the 1944–1945 Crimean outbreak, but subsequent
assessments in the Soviet Union found little evidence of benefit
(Leschinskaya, 1970). Nonetheless, immune globulin therapy was
introduced in Bulgaria, where it remains in use (Vassilev et al.,
1991; Papa et al., 2004; Christova et al., 2009). A 1990 article de-
scribed the rapid improvement of patients treated with intramus-
cular and intravenous anti-CCHF immunoglobulin, but its efficacy
has still not been assessed in a randomized clinical trial (Vass-
ilenko et al., 1990). In the 1985 nosocomial outbreak in South Afri-
ca, clinicians prepared hyperimmune serum from recovering
individuals and administered it to 6 patients, and noted that 4 of
them showed transient improvement in symptoms (van Eeden
et al., 1985b). Similarly, a study of hyperimmune globulin therapy
in Turkey described clinical improvement of patients following
treatment, but it did not include a control group (Kubar et al.,
2011).
9.4. Other antiviral therapies
Type I interferon (IFN) inhibits CCHFV replication in vitro; the
mechanism appears to include the induction of MxA expression
(Andersson et al., 2004; Andersson et al., 2006; Karlberg et al.,
2010). In the only reported clinical use, human IFN was given to
6 patients in the 1985 Tygerberg outbreak in South Africa, but no
benefit was observed (van Eeden et al., 1985b).
10. Pathogenesis of CCHF
When CCHF was first identified in 1944, it was clear that its ma-
jor pathologic abnormality was vascular dysfunction, resulting in
hemorrhage and loss of fluid from the plasma into the interstitial
space. Soviet clinicians referred to the disease as ‘‘infectious capil-
lary toxicosis,’’ based on autopsy findings that ‘‘the main patho-
logic process in the organs is caused by blood circulatory
disturbances, chiefly in capillaries and small vessels. . .’’ (Grash-
chenkov, 1945). Since that time, it has been found that CCHF pa-
tients display abnormal coagulation parameters from an early
stage of illness, and that severe disease is characterized by dissem-
inated intravascular coagulation (DIC) (Burt et al., 1997; Swane-
poel et al., 1989). However, it is not known whether vascular
dysfunction is brought about directly, through viral infection of
the endothelium, or indirectly, through the effects of circulating
proinflammatory mediators.
The only current evidence that CCHFV can directly infect the
human vasculature is a 1997 report on necropsies of 12 cases,
which described the detection of viral RNA and antigens in
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mononuclear phagocytes, hepatocytes and endothelial cells (Burt
et al., 1997). However, the presence of virus in the endothelium
at the time of death does not necessarily mean that it was the
cause of increased vascular permeability, which apparently begins
soon after the onset of illness. Instead, vascular leak, a procoagu-
lant state and hemorrhage can all be brought about by an intense
systemic inflammatory response, and are typical features of septic
shock induced by Gram-negative bacterial infection (Bray and
Mahanty, 2003). Laboratory animal studies of Ebola HF, which
shares many features with CCHF, suggest that altered vascular
function results from host-induced mechanisms, including the
induction of proinflammatory cytokines, platelet aggregation and
degranulation, leukocyte adhesion and activation of the intrinsic
coagulation cascade (Mahanty and Bray, 2004; Schnittler and Feld-
mann, 2003). Two recent studies in Turkey found that serummark-
ers of vascular activation, including sICAM-1 and sVCAM-1, were
elevated in CCHF patients, and were higher in fatal cases (Ozturk
et al., 2010; Bodur et al., 2010); conflicting results were obtained
for the marker VEGF. CCHFV infection of cultured human endothe-
lial cells has been shown to cause up-regulation of ICAM-1 and
VCAM-1 and the secretion of IL-6 and IL-8 (Connolly-Andersen
et al., 2009).
The importance of proinflammatory cytokine responses in the
pathogenesis of CCHF is supported by several reports. In a study
of mild and severe cases in Turkey, high serum levels of TNF-awere
associated with serious illness, while IL-6 was elevated in bothmild
and severe cases (Ergonul et al., 2006b). The levels of both media-
tors were significantly higher in fatal than in nonfatal cases. In a
large study in Kosovo, fatally infected CCHF patients had high levels
of IFN-c, TNF-a and interleukin (IL)-10 (Saksida et al., 2010); simi-
larly, an Albanian patient dying of the disease had high serum levels
of TNF-a, sTNF-R, IL-6, and IL-10 (Papa et al., 2006). These clinical
observations are mirrored in laboratory studies showing that
CCHFV replicates in human monocyte-derived dendritic cells
(DCs), which release proinflammatory cytokines (Connolly-Ander-
sen et al., 2009). Supernatants of infected DCs activated cultured
endothelial cells, but this could be blocked by antibodies to TNF-
a. Peyrefitte and colleagues also showed that CCHFV infection of
primary humanmacrophages and DCs induced the release of proin-
flammatory cytokines (though levels were higher in cells infected
with Dugbe virus, a nairovirus that produces only a moderately se-
vere febrile illness in humans) (Peyrefitte et al., 2010).
As noted above, many of these findings are replicated in CCHFV-
infected STAT-1 KO mice, which develop elevated serum levels of
IL-6, IL-10, IFN-c and TNF-a early in the course of illness (Bente
et al., 2010). A loss of lymphocytes through apoptosis, which oc-
curs in Ebola HF through the action of inflammatory mediators,
may also occur in CCHF. Recent studies in Turkey and Greece have
also documented the occurrence of reactive hemophagocytic lym-
phohistiocytosis in many patients, which could contribute to pan-
cytopenia (Karti et al., 2004; Tasdelen Fisgin et al., 2008; Papa
et al., 2009a). This phenomenon may reflect intense activation of
monocytes by high levels of Th1 cytokines.
The lack of animal models of CCHF has hindered research on
mechanisms of protective immunity. However, the fact that IFN-
KO mice are susceptible to lethal infection indicates the critical
role of this antiviral mechanism (Bente et al., 2010; Bereczky
et al., 2010). Nitric oxide (NO), a mediator of innate responses, also
suppresses CCHFV replication (Simon et al., 2006). A recent study
found that natural killer (NK) cells appear to play a role in the host
response to CCHF, as greater numbers of circulating NK cells were
observed in severe than mild cases, as indicated by serum liver en-
zyme levels; the highest counts were seen in two fatal cases (Yil-
maz et al., 2008). Another study showed a higher percentage of
cytotoxic T cells among circulating lymphocytes in fatal than
nonfatal cases; the percentage correlated with viral load (Akinci
et al., 2009). As noted, fatally infected CCHF patients typically do
not produce detectable IgM or IgG antibodies to the virus, indicat-
ing the protective role of the humoral response; whether this fail-
ure is linked to the loss of lymphocytes through apoptosis is
unclear.
10.1. Histopathology
Because of the sporadic nature of the disease and safety con-
cerns in performing necropsies, only a few reports have described
histologic abnormalities in fatal cases of CCHF (Baskerville et al.,
1981; Joubert et al., 1985; Burt et al., 1997). The principal findings
in the liver were eosinophilic necrosis, Kupffer cell hyperplasia and
the presence of ‘‘Councilman bodies’’ (eosinophilic necrotic hepa-
tocytes); the overall severity ranged from mild necrosis to wide-
spread damage of hepatic lobules (Burt et al., 1997). Prominent
splenic lymphoid apoptosis, with marked lymphocyte depletion,
and interstitial pneumonia were also observed.
STAT1-KO mice infected with the 10,200 strain of CCHFV
showed pathologic changes at necropsy similar to those seen in
humans (Bente et al., 2010). Gross examination of viscera showed
petechial hemorrhages of the serosa and intestinal hyperemia,
while microscopic study revealed multiple foci of hepatocellular
necrosis and prominent lymphocyte depletion and karyrrhectic
debris in the spleen, consistent with lymphocyte apoptosis.
11. Laboratory animal models of CCHF
Although Soviet scientists claimed the successful transmission of
CCHFV to a variety of laboratory animals soon after the 1944 Crimea
outbreak, these infections were subsequently recognized to be the
result of microbial contamination (Grashchenkov, 1945). Since that
time, many researchers have tried unsuccessfully to reproduce the
features of human CCHF inmice, rats, hamsters, guinea pigs, rabbits
and other laboratory animals (Nalca and Whitehouse, 2007), but
only newborn mice were found to be susceptible to infection (see
below). Unlike the filoviruses, which produce severe hemorrhagic
fever in humans and in all nonhumanprimate species tested, CCHFV
has not been reported to cause disease in any laboratory primate,
though results have been published only for African greenmonkeys,
baboons, and patas monkeys (Butenko et al., 1968; Fagbami et al.,
1975; Smirnova, 1979). The failure of CCHFV to cause illness in com-
mon laboratory animals has seriously impaired efforts to develop
new antiviral drugs and vaccines against the disease.
In vivo laboratory studies of CCHF still focus entirely on its rep-
lication in mice. Adult, immunocompetent mice are resistant to the
virus, but reports in the 1960s demonstrated that it replicates to
high titer in newborn mice when inoculated by the intracerebral
or intraperitoneal route (Smirnova, 1979; Tignor and Hanham,
1993). More detailed studies revealed high virus titers in the blood
and liver, with infection of macrophages and systemic viral dis-
semination (Tignor and Hanham, 1993). Although newborn mice
can be used to evaluate antiviral drugs that directly inhibit viral
replication, they cannot be employed to investigate the pathogen-
esis of CCHF, elucidate immune responses or assess the protective
efficacy of vaccines.
Recent success in developing an infection model in adult mice
lacking a type I IFN response were based on in vitro findings that
IFN plays a critical role in controlling CCHFV replication (Anders-
son et al., 2006). Two recent studies using knockout (KO) mice
lacking the cell-surface IFN-a,b receptor (Bereczky et al., 2010) or
the intracellular signal transducer and activator of transcription
(STAT)-1 protein (Bente et al., 2010) have shown the importance
of the type I IFN response in controlling disease manifestations.
IFN receptor-KO mice develop a rapidly progressive disease, with
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high tissue viral RNA levels and hepatomegaly. Similarly, STAT1-
KO mice develop a lethal systemic infection after exposure to small
quantities of CCHFV; many of the clinical manifestations, hemato-
logic and serum chemistry abnormalities, histopathologic changes
and immune responses in mice resemble those in CCHF patients
(Bente et al., 2010). The mice develop leukopenia and thrombocy-
topenia, and show progressive elevation of ALT in the serum. High-
level viral replication in the spleen is accompanied by depletion of
lymphocytes, consistent with apoptosis, while hepatic infection re-
sults in extensive necrosis. Like human patients, infected mice
showed elevated levels of circulating IL-6, IL-10 and TNF-a. KO
mice express IFN-stimulated genes later in the illness than normal
mice, explaining their inability to prevent early viral dissemination
(Bowick et al., 2012).
Despite their lack of a functional type I IFN response, IFN-recep-
tor- and STAT1-KO mice can still be used to study CCHF pathogen-
esis, test the virulence of individual virus strains, evaluate novel
antiviral therapeutics and assess cross-protective immunity in-
duced by candidate vaccines. Alternatively, researchers who lack
access to BSL-4 containment might perform experiments using an-
other member of the CCHFV serogroup, Hazara virus, which also
causes lethal disseminated infection in type I IFN receptor-KO
mice, with histopathological changes similar to those described
above (Dowall et al., 2012a). This model could potentially be used
for initial in vivo screening of antiviral drugs; however, because
Hazara virus is apparently avirulent for humans, efficacy against
Hazara virus in mice may not accurately predict drug activity
against CCHFV in humans.
12. Vaccines
A formalin-inactivated mouse-brain CCHF vaccine was devel-
oped in the Soviet Union and approved for use in 1970 (Tkachenko
et al., 1970). Testing of serum samples from several thousand
recipients demonstrated that repeated vaccination induced a
low-level neutralizing antibody response; however, its protective
efficacy was not evaluated (Tkachenko et al., 1971). A similar vac-
cine continues to be used in Bulgaria, where it is given to soldiers,
medical personnel and other high-risk groups in endemic areas
(Papa et al., 2004) (Christova et al., 2010). Sequencing showed that
the Bulgarian V42/81 vaccine strain, isolated prior to 1970, is clo-
sely related to other viruses isolated in Bulgaria, Kosovo and Tur-
key (Papa et al., 2010). Evidence of the vaccine’s protective
efficacy is based on the recorded incidence of CCHF in the country:
in the 21 years before vaccination began in 1974, more than 1100
cases were recorded, but in the subsequent 22 years, the total was
only 279. CCHF has never been observed in vaccinated individuals
(Todorov et al., 2001). A recent study found that the Bulgarian vac-
cine elicited both a cellular and humoral response to CCHFV, but
neutralizing antibody titers were low, even in persons who had re-
ceived it 4 times (Mousavi-Jazi et al., 2012).
The lack of laboratory animal models has hampered efforts to
develop more effective vaccines for CCHF, and only two studies
have appeared in the recent literature. In the first, an experimental
multivalent DNA vaccine against Rift Valley fever, tick-borne
encephalitis, Hantaan and CCHF viruses proved to be poorly immu-
nogenic in mice (Spik et al., 2006). In a proof-of-concept study,
mice exposed orally or parentally to transgenic tobacco plants
expressing the CCHFV GN and GC developed antibodies to the virus
(Ghiasi et al., 2011).
13. Future geographic range and incidence of CCHF
A number of investigators have expressed concern that the
trend toward warmer climates in central and northern Europe
might permit CCHFV to expand outside its current geographic
range, through the introduction of infected Hyalomma or other res-
ervoir ticks by migratory birds or the international livestock trade
(Gray et al., 2009; Estrada-Pena et al., 2012e; Heyman et al., 2010;
Maltezou and Papa, 2010; Mild et al., 2010). It has long been
known that larvae and nymphs of ticks indigenous to the Mediter-
ranean region and Africa can be found on birds returning to central
and northern Europe from their winter migration. For example,
investigators recently identified immature H. marginatum on sev-
eral species of birds in the United Kingdom, and estimated that
tens of thousands of such ticks arrive each spring (Jameson et al.,
2012). Similarly, the African tick H. rufipes has been recovered from
birds as far north as Norway (Hasle et al., 2009). As it has been gen-
erally believed that lower mean environmental temperatures north
of the Balkans, Alps and Pyrenees (north of 50 latitude) would pre-
vent these thermophilic ticks from reaching adulthood, the discov-
ery of a matureH. marginatum attached to a person in Germany
(Kampen et al., 2007) and of adult ticks of the African species H.
rufipes feeding on cattle in Hungary (Hornok and Horvath, 2012)
was sufficiently unusual to warrant a published report.
Minimum or mean winter temperatures do not appear to be sig-
nificant factors determining the geographic range of CCHFV vec-
tors, as adult ticks can usually survive prolonged cold (Turell,
2007). Instead, a low cumulative autumn temperature, which pre-
vent the completion of molting of nymphs to adults, appears to be
the principal barrier to the spread of competent tick vectors north-
wards into Europe (Gray et al., 2009; Estrada-Pena et al., 2012d). In
addition to the ability to complete the maturation cycle, the estab-
lishment of a stable population of Hyalomma or other ticks in a new
area requires that newly introduced males and female ticks are
able to locate each other, for purposes of copulation, and that they
are able to find small and large vertebrates for their blood meals.
Although it is possible that global warming will eventually raise
temperatures in central Europe to those required for Hyalomma
ticks to reach adulthood before the onset of cold weather, a recent
mathematical analysis concluded that the establishment of new
enzootic foci of CCHF is very unlikely in the foreseeable future
(Gale et al., 2011).
The above scenarios are based upon the introduction of compe-
tent tick vectors of CCHFV into new regions. A more realistic fear
is that the virus might expand its range to countries such as Italy
and Spain, where Hyalomma ticks are already present, but CCHF
has not been reported. As noted above, this concern was rein-
forced by the recent detection of CCHFV RNA in H. lusitanicum
recovered from wild deer in Spain (Estrada-Pena et al., 2012c).
Careful monitoring for human infections in these countries is
clearly indicated.
Another route by which CCHFV might expand its geographic
range would be to ‘‘jump’’ to ticks other than its current vectors,
such as the various ixodid ticks that now transmit tick-borne
encephalitis in central Europe and Russia. The opportunity for such
a host-switch might occur if ticks of more than one species feed on
the same viremic host, or if infected and uninfected ticks of two
different species take blood meals in close proximity. Such trans-
mission between tick species presumably occurs in areas such as
Turkey, where CCHFV circulates widely and more than one compe-
tent vector is present. Careful study of the vector competence of
ticks in regions neighboring CCHF-endemic areas is warranted, to
evaluate this potential route of virus spread.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.antiviral.2013.
07.006.
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